

10536687

Connecting via Winsock to STM

Welcome to STN International! Enter x:x

LOGINID: ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 3 APR 15 WPIDS, WPIDEX, and WPIX enhanced with new predefined hit display formats
NEWS 4 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 5 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 6 MAY 30 INFAPAMDB now available on STN for patent family searching
NEWS 7 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 8 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 9 JUN 06 KOREPAT updated with 41,000 documents
NEWS 10 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 11 JUN 19 CAS REGISTRY includes selected substances from web-based collections
NEWS 12 JUN 25 CA/Cplus and USPAT databases updated with IPC reclassification data
NEWS 13 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 14 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 15 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 16 JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 17 JUL 28 CA/Cplus patent coverage enhanced
NEWS 18 JUL 28 EPFULL enhanced with additional legal status information from the epoline Register
NEWS 19 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20 JUL 28 STN Viewer performance improved
NEWS 21 AUG 01 INFADOCDB and INFAPAMDB coverage enhanced
NEWS 22 AUG 13 CA/Cplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 23 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 24 AUG 15 CAplus currency for Korean patents enhanced
NEWS 25 AUG 25 CA/Cplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching
NEWS 26 AUG 27 CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence

10536687

			information
NEWS 27	SEP 18		Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 28	SEP 25		CA/CAPLus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 29	SEP 26		WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS 30	SEP 29		IFICLs enhanced with new super search field
NEWS 31	SEP 29		EMBASE and EMBAL enhanced with new search and display fields
NEWS 32	SEP 30		CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:42:15 ON 03 OCT 2008

FILE 'REGISTRY' ENTERED AT 16:42:27 ON 03 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 OCT 2008 HIGHEST RN 1056546-78-1
DICTIONARY FILE UPDATES: 2 OCT 2008 HIGHEST RN 1056546-78-1

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

10536687

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=>
Uploading C:\Documents and Settings\brobinson1\My Documents\e-Red
Folder\10524345\bhu.str
```

L1 STRUCTURE UPLOADED

```
=> s lkl           30 LK1
L2
```

```
=> s 11
SAMPLE SEARCH INITIATED 16:46:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       1509 TO ITERATE
```

```
100.0% PROCESSED       1509 ITERATIONS                           21 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:   ONLINE   **COMPLETE**
                          BATCH    **COMPLETE**
PROJECTED ITERATIONS:    27850 TO    32510
PROJECTED ANSWERS:       146 TO      694
```

L3 21 SEA SSS SAM L1

```
=> s 11 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:47:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       30821 TO ITERATE
```

```
100.0% PROCESSED       30821 ITERATIONS                           367 ANSWERS
SEARCH TIME: 00.00.01
```

L4 367 SEA SSS FUL L1

```
=> file hcplus
COST IN U.S. DOLLARS                                           SINCE FILE
                                                                         ENTRY     TOTAL
                                                                         SESSION
FULL ESTIMATED COST                                            186.73    186.94
```

```
FILE 'HCPLUS' ENTERED AT 16:47:13 ON 03 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is

10536687

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Oct 2008 VOL 149 ISS 15
FILE LAST UPDATED: 2 Oct 2008 (20081002/ED)

HCPlus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 14
L5          37 L4

=> s 15 and gravestock, m?/au
     86 GRAVESTOCK, M?/AU
L6          6 L5 AND GRAVESTOCK, M?/AU

=> d 16, ibib abs hitstr, 1-6

L6  ANSWER 1 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:954100 HCPLUS
DOCUMENT NUMBER: 147:479761
TITLE: Novel Substituted (Pyridin-3-yl)phenyloxazolidinones:
        Antibacterial Agents with Reduced Activity against
        Monoamine Oxidase A and Increased Solubility
AUTHOR(S): Reck, Folkert; Zhou, Fei; Eyermann, Charles J.; Kern,
           Gunther; Carcanague, Dan; Ioannidis, Georgine;
           Illingworth, Ruth; Poon, Grace; Gravestock,
           Michael B.
CORPORATE SOURCE: AstraZeneca Discovery, AstraZeneca R&D Boston,
                   Waltham, MA, 02451, USA
SOURCE: Journal of Medicinal Chemistry (2007), 50(20),
        4868-4881
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:479761
GI
```



AB Oxazolidinones represent a new and promising class of antibacterial agents. Current research in this area is mainly concentrated on improving the safety profile and the antibacterial spectrum. Oxazolidinones bearing a (pyridin-3-yl)phenyl moiety (e.g., 3) generally show improved antibacterial activity compared to linezolid but suffer from potent monoamine oxidase A (MAO-A) inhibition and low solubility. We now disclose the finding that new analogs of 3 with acyclic substituents on the pyridyl moiety exhibit excellent activity against Gram-pos. pathogens, including linezolid-resistant *Streptococcus pneumoniae*. Generally, more bulky substituents yielded significantly reduced MAO-A inhibition relative to the unsubstituted compound 3. The MAO-A SAR can be rationalized on the basis of docking studies using a MAO-A/MAO-B homol. model. Solubility was enhanced with incorporation of polar groups. One optimized analog, compound 13(I), showed low clearance in the rat and efficacy against *S. pneumoniae* in a mouse pneumonia model.

IT 870694-12-5P 870694-13-6P 870694-25-0P
870694-35-2P 870761-58-3P 870761-61-8P
870761-77-6P 870807-38-8P 953781-74-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(Novel Substituted (Pyridin-3-yl)phenyloxazolidinones: Antibacterial Agents with Reduced Activity against Monoamine Oxidase A and Increased Solubility)

RN 870694-12-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1R)-1-hydroxyethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 870694-13-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1S)-1-hydroxyethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870694-25-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(hydroxymethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 870694-35-2 HCAPLUS
CN 2-Pyridinecarboxaldehyde, 5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870761-58-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[4-(4-methyl-1-piperazinyl)-1-oxobutyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

10536687




RN 870761-61-8 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[(5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]carbonyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



10536687

PAGE 2-A




RN 870761-77-6 HCAPLUS


CN 1-Azetidinecarboxylic acid, 3-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]carbonyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




10536687

RN 870807-38-8 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[6-(3-azetidinylcarbonyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 953781-74-3 HCAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



IT 870694-07-8P 870694-40-9P 870714-90-2P
 870751-81-8P 870751-82-9P 870751-83-0P
 870761-53-8P 870761-56-1P 870761-57-2P
 870761-59-4P 870761-62-9P 870761-65-2P
 870761-66-3P 870807-32-2P 870807-33-3P
 870807-34-4P 870807-35-5P 870807-36-6P
 870807-37-7P 953781-64-1P 953781-73-2P
 953781-75-4P 953781-78-7P 953781-79-8P
 953781-80-1P 953781-82-3P 953781-85-6P
 953781-99-2P 953782-01-9P 953782-04-2P
 953782-07-5P 953782-09-7P 953782-12-2P
 953782-14-4P 953782-15-5P 953782-16-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (Novel Substituted (Pyridin-3-yl)phenyloxazolidinones: Antibacterial
 Agents with Reduced Activity against Monoamine Oxidase A and Increased
 Solubility)
 RN 870694-07-8 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1-hydroxy-1-methylethyl)-3-
 pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 870694-40-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[2-(2,5-dimethyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870714-90-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[1-hydroxy-2-(4-morpholinyl)ethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 870751-81-8 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[1-hydroxy-2-(4-morpholinyl)ethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870751-82-9 HCPLUS
CN 2-Oxazolidinone, 3-[4-[6-[2-(dimethylamino)-1-hydroxyethyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 870751-83-0 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1-hydroxy-2-[(1-methylethyl)amino]ethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870761-53-8 HCPLUS

CN 2-Oxazolidinone, 3-[4-(6-acetyl-3-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 870761-56-1 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(4-methyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 870761-57-2 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(4-piperidinyl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 870761-59-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[4-(4-methyl-1-piperazinyl)-1-oxobutyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:2),
(5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870761-62-9 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-(3-azetidinylcarbonyl)-3-pyridinyl]-3-

10536687

fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 870761-65-2 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-[2-(2,4-dimethyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687


RN 870761-66-3 HCPLUS
CN 2-Oxazolidinone, 3-[4-[6-[2-(2-ethyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 870807-32-2 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1H-imidazol-1-yl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870807-33-3 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(4-morpholinyl)-1-oxobutyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 870807-34-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(2-methyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870807-35-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(4-methyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 870807-36-6 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(4-piperidinyl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870807-37-7 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(4-piperidinylcarbonyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A




PAGE 2-A



RN 953781-64-1 HCPLUS
CN 2-Oxazolidinone, 3-[4-[6-(3-azetidinylhydroxymethyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 953781-73-2 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[1-hydroxy-4-(4-methyl-1-piperazinyl)butyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 953781-75-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(hydroxy-4-piperidinylmethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


10536687

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 953781-78-7 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(methoxymethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 953781-79-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1R)-1-methoxyethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 953781-80-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1S)-1-methoxyethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 953781-82-3 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1-hydroxy-2-methylpropyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 953781-85-6 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[6-(1,1-dihydroxyethyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10536687



RN 953781-99-2 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-(3-azetidinylhydroxymethyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (4:11), (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 953782-01-9 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1H-imidazol-1-yl)acetyl]-3-

10536687

pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1),
(5R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 953782-04-2 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(6-[2-(2-methyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (5:1),
(5R)- (CA INDEX NAME)

Absolute stereochemistry.



●1/5 HCl


10536687

RN 953782-07-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[1-hydroxy-4-(4-methyl-1-piperazinyl)butyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (5:14), (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


●14/5 HCl

RN 953782-09-7 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[4-(4-morpholinyl)-1-oxobutyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687




RN 953782-12-2 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(4-piperidinylcarbonyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (4:5),
(5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







● 5/4 HCl

RN 953782-14-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(5R)-5-(1H-1,2,3-triazol-1-ylmethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (2:3), (5R)- (CA INDEX NAME)

Absolute stereochemistry.






● 3/2 HCl

RN 953782-15-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:3), (5R)- (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 953782-16-6 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-[2-(dimethylamino)-1-hydroxyethyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (2:9), (5R)- (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20051292080 HCPLUS
 DOCUMENT NUMBER: 144:36354
 TITLE: Preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents
 INVENTOR(S): Gravestock, Michael Barry; Reck, Folkert; Zhou, Fei
 PATENT ASSIGNEE(S): AstraZeneca UK Limited, UK
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116023	A1	20051208	WO 2005-GB2055	20050524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TT, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				

AU 2005247670	A1	20051208	AU 2005-247670	20050524
CA 2567929	A1	20051208	CA 2005-2567929	20050524
EP 1753755	A1	20070221	EP 2005-746538	20050524
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1989134	A	20070627	CN 2005-80025002	20050524
BR 2005011524	A	20071226	BR 2005-11524	20050524
JP 2008500318	T	20080110	JP 2007-514088	20050524
US 2008021071	A1	20080124	US 2006-569208	20061116
IN 2006DN07661	A	20070817	IN 2006-DN7661	20061218
NO 2006005902	A	20070220	NO 2006-5902	20061219
KR 2007023765	A	20070228	KR 2006-727032	20061222
PRIORITY APPLN. INFO.:			GB 2004-11592	A 20040525
			GB 2005-53	A 20050105
			WO 2005-GB2055	W 20050524

OTHER SOURCE(S): MARPAT 144:36354
GI



AB Title compds. I [R1 = H, halo, CN, etc.; R2-3 = H, F, Cl, CF₃; R4 = alkyl, alkoxy, hydroxyalkoxy, etc.] are prepared For instance, II is prepared by the coupling of 1-(5-bromopyridin-2-yl)-2-(morpholin-4-yl)ethanol (preparation given) and (R)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-(1H-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (preparation given) (DMF, (Ph3P)4P, 75°, 3 h). Compds. of the invention exhibit good antibacterial activity against standard Gram-pos. organisms with a MIC in the range of 0.01-256 µg/mL. I also exhibit relatively low levels of MAO-A inhibition.

IT 870694-16-9P 870694-25-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents)

RN 870694-16-9 HCPLUS

10536687

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1-hydroxy-3-oxobutyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870694-25-0 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(hydroxymethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 870694-06-7P 870694-07-8P 870694-08-9P

10536687

870694-09-0P 870694-10-3P 870694-11-4P
870694-12-5P 870694-13-6P 870694-14-7P
870694-15-8P 870694-17-0P 870694-18-1P
870694-19-2P 870694-20-5P 870694-21-6P
870694-22-7P 870694-23-8P 870694-24-9P
870694-27-2P 870714-90-2P 870714-91-3P
870714-92-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents)

RN 870694-06-7 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-(1,2-dihydroxyethyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870694-07-8 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 870694-08-9 HCPLUS
CN 2-Oxazolidinone, 3-[4-[6-[(2,3-dihydroxypropyl)methylamino]methyl]-3-pyridinyl]-3-fluorophenyl-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870694-09-0 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(2-hydroxyethyl)methylamino]methyl]-3-

10536687

pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870694-10-3 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[(dimethylamino)methyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




10536687


RN 870694-11-4 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(4-morpholinylmethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 870694-12-5 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1R)-1-hydroxyethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687





RN 870694-13-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1S)-1-hydroxyethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 870694-14-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-[[bis(2-hydroxyethyl)amino]methyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 870694-15-8 HCPLUS

CN 4-Morpholinecarboxylic acid, [5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 870694-17-0 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(1,3-dihydroxybutyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 870694-18-1 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-(cyclopropylhydroxymethyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870694-19-2 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(methylsulfinyl)methyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 870694-20-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(methylsulfonyl)methyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687


RN 870694-21-6 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(methylthio)methyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 870694-22-7 HCPLUS
CN 2-Oxazolidinone, 3-[4-[6-[2-(2,5-dimethyl-1H-imidazol-1-yl)-1-hydroxyethyl]-3-pyridinyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870694-23-8 HCPLUS
CN 2-Pyridinecarbonitrile, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 870694-24-9 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(6-methyl-3-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870694-27-2 HCPLUS

CN 2-Pyridinecarbonitrile, 5-[2-fluoro-4-[(5R)-5-((4-methyl-1H-1,2,3-triazol-1-yl)methyl)-2-oxo-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 870714-90-2 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[1-hydroxy-2-(4-morpholinyl)ethyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870714-91-3 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-[2-(dimethylamino)-1-hydroxyethyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


10536687



RN 870714-92-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[(1-hydroxy-2-[(1-methylethyl)amino]ethyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 870694-35-2P 870694-38-5P 870694-39-6P

870694-40-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


10536687

(preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents)

RN 870694-35-2 HCPLUS

CN 2-Pyridinecarboxaldehyde, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 870694-38-5 HCPLUS

CN Carbamimidothioic acid, [5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.




10536687

RN 870694-39-6 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-(bromomethyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870694-40-9 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-[2-(2,5-dimethyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20051291974 HCPLUS
 DOCUMENT NUMBER: 144:36352
 TITLE: Preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents
 INVENTOR(S): Gravestock, Michael Barry; Reck, Folkert;
 Zhou, Fei
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116022	A1	20051208	WO 2005-GB2051	20050524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005247668	A1	20051208	AU 2005-247668	20050524
CA 2566963	A1	20051208	CA 2005-2566963	20050524
EP 1753754	A1	20070221	EP 2005-746537	20050524
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1989137	A	20070627	CN 2005-80025063	20050524
BR 2005011526	A	20071226	BR 2005-11526	20050524
JP 2008500317	T	20080110	JP 2007-514087	20050524
US 20080021012	A1	20080124	US 2006-569408	20061120
MX 2006PA13537	A	20070126	MX 2006-PA13537	20061122
IN 2006DN07668	A	20070817	IN 2006-DN7668	20061218
NO 2006005889	A	20070220	NO 2006-5889	20061219
KR 2007023766	A	20070228	KR 2006-727033	20061222
PRIORITY APPLN. INFO.:			GB 2004-11593	A 20040525
			GB 2005-54	A 20050105
			WO 2005-GB2051	W 20050524
OTHER SOURCE(S):	CASREACT 144:36352; MARPAT 144:36352			
GI				



AB Title compds. I [R1 = H, halo, CN, etc.; R2-3 = H, F, Cl, CF₃; R4 = carboxy, etc.] are prepared. For instance, II is prepared by the coupling of 1-(5-bromopyridin-2-yl)-2-(1H-imidazol-1-yl)ethanone (preparation given) and (R)-3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (preparation given) (DMF, (Ph₃P)₄P, 75°, 3 h). Compds. of the invention exhibit good antibacterial activity against standard Gram-pos. organisms with a MIC in the range of 0.01-256 µg/mL. I also exhibit relatively low levels of MAO-A inhibition compared to similarly substituted analogs.


IT 870694-35-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents)

RN 870694-35-2 HCPLUS

CN 2-Pyridinecarboxaldehyde, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 870694-40-9P 870761-50-5P 870761-51-6P
 870761-52-7P 870761-53-8P 870761-54-9P
 870761-55-0P 870761-56-1P 870761-57-2P
 870761-58-3P 870761-59-4P 870761-60-7P
 870761-61-8P 870761-62-9P 870761-63-0P
 870761-64-1P 870761-65-2P 870761-66-3P
 870761-67-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents)

RN 870694-40-9 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-[2-(2,5-dimethyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 870761-50-5 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(1H-imidazol-1-yl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:?), (5R)- (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 870761-51-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[4-(4-morpholinyl)-1-oxobutyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:?), (5R)- (CA INDEX NAME)

Absolute stereochemistry.

10536687




RN 870761-52-7 HCPLUS

CN 2-Pyridinecarboxaldehyde, 5-[2-fluoro-4-((5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2-[0-(1,1-dimethylethyl)oxime] (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 870761-53-8 HCPLUS

CN 2-Oxazolidinone, 3-[4-(6-acetyl-3-pyridinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Updated Search

10536687

Absolute stereochemistry.




RN 870761-54-9 HCPLUS

CN 2-Pyridinecarboxaldehyde, 5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2-oxime (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 870761-55-0 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(2-methyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

10536687

Absolute stereochemistry.




● HCl

RN 870761-56-1 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(6-[2-(4-methyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 870761-57-2 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(6-[2-(4-piperidinyl)acetyl]-3-

10536687

pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1),
(5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870761-58-3 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[4-(4-methyl-1-piperazinyl)-1-oxobutyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687



RN 870761-59-4 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[4-(4-methyl-1-piperazinyl)-1-oxobutyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:2),
(5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 870761-60-7 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-(4-piperidinylcarbonyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1),
(5R)- (CA INDEX NAME)

Absolute stereochemistry.





● HCl

RN 870761-61-8 HCPLUS

CN 1-Piperidinecarboxylic acid, 4-[{[5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]carbonyl}-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 870761-62-9 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[6-(3-azetidinylcarbonyl)-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)-(CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 870761-63-0 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(2-propyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 870761-64-1 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-[2-(1-methylethyl)-1H-imidazol-1-yl]acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 870761-65-2 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-[2-(2,4-dimethyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]-5-(1H-1,2,3-triazol-1-ylmethyl)], (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 870761-66-3 HCPLUS


CN 2-Oxazolidinone, 3-[4-[6-[2-(2-ethyl-1H-imidazol-1-yl)acetyl]-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)], (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 870761-67-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(methoxymethyl)-1H-imidazol-1-yl]acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-
 (CA INDEX NAME)

Absolute stereochemistry.




IT 870761-77-6P 870807-36-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 3-[4-(pyridin-3-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)oxazolidin-2-ones as antibacterial agents)
 RN 870761-77-6 HCAPLUS
 CN 1-Azetidinecarboxylic acid, 3-[(5-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-2-pyridinyl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A




PAGE 2-A



RN 870807-36-6 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[6-[2-(4-piperidinyl)acetyl]-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:467876 HCPLUS
 DOCUMENT NUMBER: 141:23521
 TITLE: Preparation of substituted oxazolidinones as antibiotics
 INVENTOR(S): Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048350	A2	20040610	WO 2003-GB5091	20031124
WO 2004048350	A3	20041021		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507628	A1	20040610	CA 2003-2507628	20031124
AU 2003285509	A1	20040618	AU 2003-285509	20031124

EP 1581524	A2	20051005	EP 2003-778506	20031124
R: AT, BE, CH, IE, SI, LT,	DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003016690	A	20051018	BR 2003-16690	20031124
CN 1742009	A	20060301	CN 2003-80109183	20031124
JP 2006515601	T	20060601	JP 2005-510254	20031124
MX 2005PA05522	A	20050725	MX 2005-PA5522	20050524
ZA 2005004309	A	20060222	ZA 2005-4309	20050526
US 20060116386	A1	20060601	US 2005-536687	20050527
NO 200503133	A	20050715	NO 2005-3133	20050627
PRIORITY APPLN. INFO.:			GB 2002-27704	A 20021128
OTHER SOURCE(S):	MARPAT 141:23521		GB 2003-10828	A 20030510
GI			WO 2003-GB5091	W 20031124

PRIORITY APPLN. INFO.: MARPAT 141:23521
 OTHER SOURCE(S): WO 2003-GB5091



AB Title compds. I [C = substituted biaryl; R1 = HET1, HET2; HET1 = N-linked 5-membered (un)saturated heterocyclic ring, etc.; HET2 = N-linked 6-membered dihydroheteroaryl ring, etc.] are prepared. For instance, (5R)-3-(3-fluoro-4-iodophenyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one (preparation given) is coupled to bis(pinacolato)diboron (DMSO, PdCl₂(dpdf)-CH₂C₁₂, KOAc) and the resulting adduct coupled to 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (DMF, H₂O, K₂CO₃, (PPh₃)₄Pd) to give II. Compds. of the invention exhibit antibacterial activity with MIC = 0.01 - 256 µg/mL; II has MIC < 0.06 for *Streptococcus pneumoniae*.
IT 700370-55-4P, (5R)-3-[3-Fluoro-4-[2-methyl-6-(4-methyl-1H-1,2,3-triazol-1-yl)pyridin-3-yl]phenyl]-5-[(1H-1,2,3-triazol-1-yl)methyl]-1,3-

oxazolidin-2-one


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted oxazolidinones as antibiotics)

RN 700370-55-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[2-methyl-6-(4-methyl-1H-1,2,3-triazol-1-yl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:696894 HCPLUS

DOCUMENT NUMBER: 139:214458

TITLE: Preparation of 3-cyclyl-5-((nitrogen-containing 5-membered ring)methyl)oxazolidinones and their use as antibacterial agents

INVENTOR(S): Gravestock, Michael Barry; Hales, Neil
James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert;
Carcanague, Daniel Robert; Girardot, Marc Michel

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072575	A1	20030904	WO 2003-GB785	20030225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2477344 A1 20030904 CA 2003-2477344 20030225
 AU 2003207340 A1 20030909 AU 2003-207340 20030225
 BR 2003008056 A 20041207 BR 2003-8056 20030225
 EP 1497286 A1 20050119 EP 2003-704812 20030225
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 CN 1649866 A 20050803 CN 2003-809171 20030225
 JP 2005524661 T 20050818 JP 2003-571281 20030225
 NZ 535592 A 20060728 NZ 2003-535592 20030225
 MX 2004PA08312 A 20041126 MX 2004-PA8312 20040826
 US 20050119292 A1 20050602 US 2004-506020 20040826
 ZA 2004006812 A 20050912 ZA 2004-6812 20040826
 NO 2004003950 A 20041013 NO 2004-3950 20040921
 IN 2006DN06624 A 20070831 IN 2006-DN624 20061108
 PRIORITY APPLN. INFO.: MARPAT 139:214458 P 20020228
 GI WO 2003-GB785 W 20030225
 IN 2004-DN2480 A3 20040825

OTHER SOURCE(S):

MARPAT 139:214458

GI



AB 3-Cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-methyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is (1-4C)alkyl; Q = for example, 3-R2-4-T-5-R3phenyl wherein R2 and R3 = H or fluoro; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with

0-2 O atoms bonded to S), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compns. containing them are

described. Compds. I have a good spectrum of activity in vitro against standard organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive *Staphylococcus aureus* and against methicillin resistant and quinolone resistant *Staphylococcus aureus* are 2 and 4 μ g/mL, resp., compared to 2 and 2 μ g/mL for the reference compound without the Me substituent. Compds. I showed a favorable decreased MAO-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azolylmethyl or hydroxymethyl. They also showed favorable decreased MAO-A potency compared with analogs in which the HET group is unsubstituted. Fifty-seven example preps. of intermediates and 44 example preps. of I are included. For example, to prepare II, (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-azidomethyloxazolidin-2-one (1.0 mmol; preparation described) was mixed with 5,6,7,8-tetrachloro-2,9-dimethyl-1,4-dihydro-1,4-ethenonaphthalene (2.0 mmol) in dry 1,4-dioxane (4 mL) in a sealed microwave reaction tube. The tube was placed in a Smith microwave reactor at 170° for 20 min. The reaction mixture was then transferred into a round bottom flask and the solvent was removed under vacuum. The residue was purified by chromatog. on silica gel with 5% MeOH in CH2Cl2 to give a mixture of the 4- and 5-Me regioisomers. This mixture was further separated on a chiral column (chiralcel OD) with iso-ProOH/hexanes (1:1) to give II (74 mg).

IT 591232-91-6P, (5R)-3-[4-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-96-1P, (5R)-3-[4-[1-(Acetoxyacetyl)-1,2,3,6-tetrahydropyridin-4-yl]-3-fluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of cyclol (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591232-91-6 HCPLUS


CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinylphenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 591232-96-1 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[1-[2-(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 591232-88-1P, (5R)-3-[3,5-Difluoro-4-(1-glycoloyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-93-8P, (5R)-3-[4-[1-((2S)-2,3-Dihydroxypropanoyl)-1,2,3,6-tetrahydropyridin-4-yl]-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-95-0P

, (5R)-3-[3-Fluoro-4-(1-glycoloyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591233-00-0P
(5R)-3-[4-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(5-methyl-2H-tetrazol-2-yl)methyl]oxazolidin-2-one


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of cyclal (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591232-88-1 HCPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(2-hydroxyacetyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(CA INDEX NAME)

Absolute stereochemistry.




RN 591232-93-8 HCPLUS

CN 2-Oxazolidinone, 3-[4-[1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)-(CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 591232-95-0 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(2-hydroxyacetyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 591233-00-0 HCAPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(5-methyl-2H-tetrazol-2-yl)methyl]-, (5R)- (CA INDEX NAME)

Updated Search

NAME)

Absolute stereochemistry.




IT 591232-98-3P, (5R)-3-[4-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)-3-fluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-1,3-oxazolidin-2-one
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of cyclyl (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)

RN 591232-98-3 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



- IT 591232-89-2P, (5R)-3-[4-(1-Acetoxyacetyl-1,2,3,6-tetrahydropyridin-4-yl)-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one 591232-94-9P, (5R)-3-[4-[1-[(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydropyridin-4-yl]-3,5-difluorophenyl]-5-[(4-methyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclyl (nitrogen-containing 5-membered ring)methyl oxazolidinones and their use as antibacterial agents)
- RN 591232-89-2 HCAPLUS
- CN 2-Oxazolidinone, 3-[4-[1-[2-(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 591232-94-9 HCPLUS

CN 2-Oxazolidinone, 3-[4-[1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:798227 HCPLUS

DOCUMENT NUMBER: 135:344473

TITLE: Oxazolidinone derivatives with antibacterial activity
Gravestock, Michael Barry; Betts, Michael


INVENTOR(S): John; Griffin, David Alan; Matthews, Ian Richard
Astrazeneca AB, Swed.; Astrazeneca UK Limited

PATENT ASSIGNEE(S): PCT Int. Appl., 143 pp.
SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081350	A1	20011101	WO 2001-GB1815	20010423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2405349	A1	20011101	CA 2001-2405349	20010423
BR 2001010240	A	20030107	BR 2001-10240	20010423
EP 1286998	A1	20030305	EP 2001-921669	20010423
EP 1286998	B1	20040609		
EP 1286998	B2	20071031		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003000416	A2	20030628	HU 2003-416	20010423
JP 2003531211	T	20031021	JP 2001-578439	20010423
EE 200200598	A	20040415	EE 2002-598	20010423
NZ 521765	A	20040528	NZ 2001-521765	20010423
AT 268778	T	20040615	AT 2001-921669	20010423
PT 1286998	T	20040930	PT 2001-921669	20010423
ES 2220759	T3	20041216	ES 2001-921669	20010423
AU 781784	B2	20050616	AU 2001-48636	20010423
CN 1277829	C	20061004	CN 2001-811640	20010423
IN 2002MN01363	A	20050304	IN 2002-MN1363	20021001
ZA 2002008187	A	20040211	ZA 2002-8187	20021010
NO 2002005091	A	20021209	NO 2002-5091	20021023
MX 2002PA10453	A	20030425	MX 2002-PA10453	20021023
KR 858771	B1	20080916	KR 2002-714321	20021025
US 20030216373	A1	20031120	US 2003-258355	20030506
US 7141583	B2	20061128		
HK 1053114	A1	20050218	HK 2003-105394	20030725
PRIORITY APPLN. INFO.:			GB 2000-9803	A 20000425
OTHER SOURCE(S): GI			WO 2001-GB1815	W 20010423



AB The title compds. [I; X = O, NH, S, etc.; HET = (un)substituted C-linked 5-membered heteroaryl ring containing 2-4 heteroatoms selected from N, O and S, etc.; Q = II, III, etc. (wherein R2, R3 = H, F; T = an N-linked (fully unsatd.) 5-membered heteroaryl ring system or IV; Rc = R13CO, R13SO2, R13CS, etc.; R13 = alkyl, etc.)], useful as antibacterial agents, were prepared and formulated. E.g., a multi-step synthesis of the oxazoline (R)-V which showed MIC of 0.125 µg/mL against *Staphylococcus aureus* (Oxford), was given.

IT 371194-20-6P 371194-23-9P 371194-26-2P
371194-34-2P 371194-35-3P 371194-37-5P
371194-39-7P 371194-42-2P 371194-63-7P
371194-69-3P 371194-71-7P 371194-73-9P
371194-75-1P 371194-80-8P 371194-82-0P
371194-89-7P 371194-90-0P 371195-08-3P
371195-15-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(oxazolidinone derivs. with antibacterial activity)

RN 371194-20-6 HCPLUS
CN 2-Oxazolidinone, 3-[4-(4-amino-1-piperidinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-23-9 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(methylamino)-1-piperidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-26-2 HCPLUS

CN Acetamide, 2-(acetylxy)-N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-34-2 HCPLUS

CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-35-3 HCPLUS

CN 2-Oxazolidinone, 3-[4-[(3R)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-37-5 HCAPLUS

CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-39-7 HCAPLUS

CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-42-2 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[(3S)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.

10536687




● HCl

RN 371194-63-7 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-69-3 HCPLUS

CN 2-Oxazolidinone, 3-[4-[1-[2-(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-71-7 HCPLUS

CN 2-Oxazolidinone, 3-[4-[1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-73-9 HCPLUS

CN 2-Oxazolidinone, 3-[4-[1-[2-(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 371194-75-1 HCPLUS
CN 2-Oxazolidinone, 3-[4-[1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-80-8 HCPLUS
CN 2-Oxazolidinone, 3-[4-[1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-82-0 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-[(2R)-2-hydroxy-3-(methylthio)-1-oxopropyl]-4-pyridinyl]phenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-89-7 HCPLUS

CN 2-Oxazolidinone, 3-[4-[[4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-5-(2H-tetrazol-2-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-90-0 HCPLUS

CN 2-Oxazolidinone, 3-[4-[1-[2-(acetyloxy)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-5-(2H-tetrazol-2-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-08-3 HCPLUS

CN 2-[(5R)-3-[4-[1-[2S]-3-(1,1-dimethylethoxy)-2-hydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-15-2 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-(2H-tetrazol-2-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 371194-21-7P 371194-22-8P 371194-24-0P

371194-25-1P 371194-27-3P 371194-28-4P

371194-29-5P 371194-30-8P 371194-31-9P

371194-32-0P 371194-33-1P 371194-36-4P


371194-38-6P 371194-40-0P 371194-41-1P
 371194-43-3P 371194-44-4P 371194-45-5P
 371194-53-5P 371194-54-6P 371194-65-9P
 371194-66-0P 371194-68-2P 371194-70-6P
 371194-72-8P 371194-74-0P 371194-76-2P
 371194-77-3P 371194-78-4P 371194-81-9P
 371194-83-1P 371194-84-2P 371194-87-5P
 371194-91-1P 371194-92-2P 371194-94-4P
 371194-95-5P 371194-96-6P 371194-97-7P
 371194-98-8P 371194-99-9P 371195-09-4P
 371195-17-4P 371195-18-5P 371195-19-6P
 371195-20-9P 371195-21-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (oxazolidinone derivs. with antibacterial activity)

RN 371194-21-7 HCPLUS

CN Methanesulfonamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-22-8 HCPLUS

CN Carbanic acid, [1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-24-0 HCPLUS

CN Methanesulfonamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-25-1 HCPLUS

CN Carbamic acid, [1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-

10536687

3-oxazolidinyl]phenyl]-4-piperidinyl)methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-27-3 HCPLUS

CN Acetamide, N-[1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-4-piperidinyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-28-4 HCPLUS

CN 2-Oxazolidinone, 3-[4-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-29-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(4-morpholinyl)acetyl]-1-

10536687

piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 371194-30-8 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-[(2-hydroxyethyl)methylamino]acetyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX
NAME)

Absolute stereochemistry.




10536687

RN 371194-31-9 HCPLUS

CN Acetamide, N-[2-[(2-[(4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl)amino]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-32-0 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(2-methoxyethyl)methylamino]acetyl]-1-piperazinylphenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687


RN 371194-33-1 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(2-methoxyethyl)amino]acetyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-36-4 HCPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-38-6 HCPLUS
CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl-, (2S)-2,3-dihydroxypropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-40-0 HCPLUS

CN Carbamic acid, [(3R)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 2-hydroxyethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-41-1 HCPLUS

CN Carbamic acid, [(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-43-3 HCPLUS

CN Acetamide, N-[(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-44-4 HCPLUS

CN Carbamic acid, [(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-45-5 HCPLUS

CN Methanesulfonamide, N-[(3S)-1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-53-5 HCPLUS

CN 1,3,4-Oxadiazol-2(3H)-one, 3-[[{(5R)-3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl}methyl]- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 371194-54-6 HCAPLUS
CN 1,3,4-Thiadiazol-2(3H)-one, 3-[(5R)-3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] - (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-65-9 HCAPLUS
CN 1(2H)-Pyridinecarboxaldehyde, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,6-dihydro- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

10536687



RN 371194-66-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-68-2 HCAPLUS
CN 1(2H)-Pyridinecarboxaldehyde, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3,6-dihydro- (CA INDEX NAME)

Absolute stereochemistry.


10536687



BN 371194-79-6 HCAPLUS

AN 3-(1*H*-1,2,3-triazol-1-ylmethyl)-5-(1*H*-1,2,3,6-tetrahydro-1-(2-hydroxyacetyl)-4-pyridinylphenyl)-3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(2-hydroxyacetyl)-4-pyridinyl]phenyl]-5-(1*H*-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




BN 371194-72-8 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridyl]-3,5-difluorophenyl-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-74-0 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1,2,3,6-tetrahydro-1-(2-hydroxyacetyl)-4-pyridinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 371194-76-2 HCPLUS


CN 2-Oxazolidinone, 3-[4-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-,

Updated Search

10536687

(5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-77-3 HCPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl)phenyl]-5-(2H-1,2,3-triazol-2-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687

RN 371194-78-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-81-9 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371194-83-1 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-[(2R)-2-hydroxy-3-(methylsulfonyl)-1-oxopropyl]-4-pyridinyl]phenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-84-2 HCPLUS

Updated Search

10536687

CN 2(3H)-Oxazolone, 3-[(5S)-3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-87-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]phenyl]-5-(1H-tetrazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10536687

RN 371194-91-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-5-(2H-tetrazol-2-ylmethyl)-, (5R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 371194-92-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(2-hydroxyacetyl)-4-pyridinyl]phenyl]-5-(2H-tetrazol-2-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 371194-94-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-[(1-methylethyl)sulfonyl]-4-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-95-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-(methylsulfonyl)-4-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 371194-96-6 HCPLUS

CN 2-Oxazolidinone, 3-[4-[(1R,2S)-2-oxazolidinyl]-1,2,3,6-tetrahydro-4-pyridinyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 371194-97-7 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1R,2S)-2-oxazolidinyl]-1,

10536687

[(trifluoromethyl)sulfonyl]-4-pyridinylphenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371194-98-8 HCPLUS

CN 2-Oxazolidinone, 3-[4-[1-[(3-chloropropyl)sulfonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10536687

RN 371194-99-9 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[1,2,3,6-tetrahydro-1-[(2-methoxyethyl)sulfonyl]-4-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-09-4 HCPLUS
CN 3(2H)-Isooxazolone, 2-[(5R)-3-[4-[1-[(2S)-2,3-dihydroxy-1-oxopropyl]-1,2,3,6-tetrahydro-4-pyridinyl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 371195-17-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[2-(4-morpholinyl)acetyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 371195-18-5 HCPLUS


CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[2-[(2-hydroxyethyl)methylamino]acetyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride

Updated Search

10536687

(1:1), (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-19-6 HCPLUS

CN Acetamide, N-[2-[2-[4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-oxoethyl]amino]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




RN 371195-20-9 HCPLUS

10536687

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[2-[(2-methoxyethyl)methylamino]acetyl]-1-piperazinylphenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 371195-21-0 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[2-[(2-methoxyethyl)amino]acetyl]-1-piperazinylphenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687

IT 371196-57-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxazolidinone derivs. with antibacterial activity)
RN 371196-57-5 HCPLUS
CN 2-Oxazolidinone, 3-[4-[(3R)-3-amino-1-pyrrolidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, hydrochloride (1:1), (5R)- (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 371195-29-8P 371195-31-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(oxazolidinone derivs. with antibacterial activity)
RN 371195-29-8 HCPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 371195-31-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:42:15 ON 03 OCT 2008)

FILE 'REGISTRY' ENTERED AT 16:42:27 ON 03 OCT 2008
STRUCTURE uploaded
L1
L2 30 S LK1
L3 21 S L1

L4 367 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 16:47:13 ON 03 OCT 2008
L5 37 S L4
L6 6 S L5 AND GRAVESTOCK, M?/AU

=> s 15 not 16
L7 31 L5 NOT L6

=> s 17 and hales, n?/au
L8 81 HALES, N?/AU
 0 L7 AND HALES, N?/AU


=> s 17 and reck, f?/au
L9 47 RECK, F?/AU
 0 L7 AND RECK, F?/AU

=> s 17 and zhou, f?/au
L10 3206 ZHOU, F?/AU
 0 L7 AND ZHOU, F?/AU

=> d 17, ibib abs hitstr, 1-31

L7 ANSWER 1 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:916386 HCAPLUS
DOCUMENT NUMBER: 149:224399
TITLE: Novel antimicrobials
INVENTOR(S): Jain, Rajesh; Trehan, Sanjay; Das, Jagattaran; Kaur, Gurmeet; Kanwar, Sandeep; Magadi, Sitaram Kumar
PATENT ASSIGNEE(S): Panacea Biotech Ltd., India
SOURCE: PCT Int. Appl., 69pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008090570	A1	20080731	WO 2008-IN47	20080124
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2007DE00167	A	20080912	IN 2007-DE167	20070125
PRIORITY APPLN. INFO.:			IN 2007-DE167	A 20070125
OTHER SOURCE(S):	MARPAT	149:224399		
GI				



AB The present invention relates to novel Ph oxazolidinone compds. I (R = alkoxy, organothio, organoamino, etc.; Z = halo, azido, isothiocyanato, thioalc., aryl, nitro, heteroaryl, alkoxy, organoamino, etc.; T, U, V, W = same or different, H, halo, etc.; Y = O, S, NH, organoamino, etc., n, n' = 1-4) or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compds. I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compns. comprising novel compds. I and methods of using them. The compds. of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram pos. and/or Gram neg. pathogens such as multi drug resistant *Staphylococcus* spp., *Streptococcus* spp., *Enterococcus* spp., *Bacteroides* spp., *Clostridia* spp., *H. influenza*, *Moraxella* spp., as well as acid-fast organisms such as *Mycobacterium tuberculosis* and the like. Thus, preparation of (S)-N-[3-[4-(4-ethoxy-4-oxo-4*z*-[1,4]azaphosphanin-1-yl)-3-fluorophenyl]-2-oxo-oxazolidin-5-ylmethyl]acetamide is described in several steps starting from divinylphosphinic acid Et ester and benzylamine.


IT
1042425-62-6P 1042425-63-7P 1042425-64-8P
1042425-65-9P 1042425-66-0P 1042425-67-1P
1042425-69-3P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phosphinanyl aryl oxazolidinone compds. as novel antimicrobials)

RN 1042425-62-6 HCPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10536687



RN 1042425-63-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1042425-64-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10536687



RN 1042425-65-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1042425-66-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10536687




RN 1042425-67-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1042425-69-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




IT 1042426-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of phosphinyl aryl oxazolidinone compds. as novel antimicrobials)

RN 1042426-43-6 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT:


2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:576581 HCPLUS
 DOCUMENT NUMBER: 149:176286
 TITLE: Synthesis and structure-antibacterial activity of triazolyloxazolidinones containing long chain acyl moiety
 AUTHOR(S): Phillips, Oludotun A.; Udo, Edet E.; Samuel, Santhosh M.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Safat, 13110, Kuwait
 SOURCE: European Journal of Medicinal Chemistry (2008), 43(5), 1095-1104
 CODEN: EJMCA5; ISSN: 0223-5234
 PUBLISHER: Elsevier Masson SAS
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of new piperazinylphenyl(triazolylmethyl) oxazolidinones containing a long chain acyl group at the piperazine 4-position were synthesized and evaluated against a panel of standard and clin. isolates of Gram-pos. and Gram-neg. bacteria. Derivs. having acyl groups with $\geq 9C$ showed a significant decrease in antibacterial activity. Antibacterial activity correlated pos. with heat of formation of the compds., but correlated neg. with Clog P values, surface area, ovality and mol. volume. However, no significant correlation was observed between activity and E LUMO, E HOMO and dipole, resp.
 IT 859445-42-4 859445-48-0 859445-52-6
 859445-53-7 859445-54-8
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (prep. and antibacterial activity of acylpiperazinophenyl(triazolylmethyl)oxazolidinones containing a long-chain acyl group)
 RN 859445-42-4 HCPLUS
 CN 2-Oxazolidinone, 3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687


RN 859445-48-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(1-oxopropyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-52-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687

RN 859445-53-7 HCPLUS
CN 2-Oxazolidinone, 3-[4-[4-(cyclopentylcarbonyl)-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 859445-54-8 HCPLUS
CN 2-Oxazolidinone, 3-[4-[4-(cyclohexylcarbonyl)-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






IT 1040238-01-4P 1040238-03-6P 1040238-05-8P
 1040238-07-0P 1040238-09-2P 1040238-11-6P
 1040238-13-8P 1040238-15-0P 1040238-17-2P
 1040409-21-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prep. and antibacterial activity of acylpiperazinophenyl(triazolylmethoxy)oxazolidinones containing a long-chain acyl group)

RN 1040238-01-4 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1040238-03-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10536687



RN 1040238-05-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(1-oxooctyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1040238-07-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(1-oxononyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 1040238-09-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1040238-11-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10536687



RN 1040238-13-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1040238-15-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

10536687




RN 1040238-17-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1040409-21-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2008:17214 HCPLUS
 DOCUMENT NUMBER: 148:191941
 TITLE: Method for preparation of thiadiazol contained oxazolidinone and application as antibacterial agent
 INVENTOR(S): Shi, Xiulan
 PATENT ASSIGNEE(S): Shenyang Zhonghai Biological Technology Development Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhanli Shenqing Gongkai Shuomingshu, 15pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101096369	A	20080102	CN 2006-10090788	20060630
PRIORITY APPLN. INFO.:			CN 2006-10090788	20060630
OTHER SOURCE(S):	CASREACT 148:191941			
GI				



AB The invention relates to thiadiazol contained oxazolidone its salt and/or hydrate I ($R = H, F; m = 1-4$). The salt comprises hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid etc. Title compds. were prepared from (S) - N -[3-[3-fluoro-5-substituent-4-(1-piperazinyl)phenyl]2-oxo-5-oxazolidinyl]methylacetamide and $C_1(CH_2)_mCN$ in the presence of organic base or inorg. base in polar solvent to form II, then reacting with aminothiourea in the presence of acid to provide the title products. The claimed compds. can be used for treating bacterial infection in mammalian.


IT 174649-05-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiadiazol contained oxazolidone and application as antibacterial agent)

RN 174649-05-9 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[(1,3-dihydro-1,3-dioxo-2H-isocindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.



ACCESSION NUMBER: 2007:959469 HCPLUS
 DOCUMENT NUMBER: 147:377130
 TITLE: Non-aqueous titration method for determining content
 of 3,5-disubstituted oxazolidone compounds
 INVENTOR(S): Wang, Ying; Zhu, Jin; Liu, Jinsong; Lu, Tao
 PATENT ASSIGNEE(S): Sichuan Beilike Biotechnology Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhanli Shenqing Gongkai Shuomingshu, 29pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101021487	A	20070822	CN 2007-10088397	20070319
PRIORITY APPLN. INFO.:			CN 2007-10088397	20070319
AB	The title method comprises dissolving 3,5-disubstituted oxazolidone compds. 0.1-1 g in a mixture of glacial acetic acid (or acetic anhydride) and formic acid (in an amount of 0.5-100 times in weight of 3,5-disubstituted oxazolidone compds.); adding crystal violet indicator solution 0.05-0.3 mL; titrating with 0.01-0.1 mol/L perchloric acid solution until the solution turns blue green color; and calculating the content of 3,5-disubstituted oxazolidone compds. based on defined formula. The method is simple and accurate.			
IT 948904-05-0	948904-06-1	948904-07-2		
948904-08-3				
RL: ANT (Analyte); ANST (Analytical study)				
(non-aqueous titration method for determination of disubstituted oxazolidone compds.)				
RN 948904-05-0 HCPLUS				
CN 1H-Isoindole-1,3(2H)-dione, 2-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)				


Absolute stereochemistry.



RN 948904-06-1 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(phenylmethyl)-1-piperazinyl]phenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687




RN 948904-07-2 HCAPLUS
CN 3-Azabicyclo[3.2.1]octane-2,4-dione, 3-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1,8,8-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 948904-08-3 HCAPLUS
CN 2,5-Pyrrolidinedione, 1-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 5 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20071959465 HCAPLUS
 DOCUMENT NUMBER: 147:355844
 TITLE: Method for determining content of 3,5-disubstituted oxazolidinone compounds
 INVENTOR(S): Wang, Ying; Zhu, Jin; Liu, Jinsong; Lu, Tao
 PATENT ASSIGNEE(S): Sichuan Beilike Biotechnology Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhanli Shenqing Gongkai Shuomingshu, 23pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101021512	A	20070822	CN 2007-10088396	20070319
PRIORITY APPLN. INFO.:			CN 2007-10088396	20070319
AB The title method is characterized by employing UV detector with detection wavelength of 200-400 nm, reverse phase column with column temperature of 20-50°, and a mixture of water and 30-90 volume% polar organic solvent (acetonitrile, methanol, ethanol, THF, chloroform, and/or isopropanol) as mobile phase. The method is simple and rapid, and has high stability and wide application.				
IT 556801-57-1 947736-32-5 947736-33-6 947736-35-8				
RL: ANT (Analyte); ANST (Analytical study) (method for determination of 3,5-disubstituted oxazolidinone compds.)				
RN 556801-57-1 HCAPLUS				
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-5-				

10536687

(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 947736-32-5 HCPLUS

CN 1H-Isindole-1,3(2H)-dione, 2-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 947736-33-6 HCPLUS

CN 3-Azabicyclo[3.2.1]octane-2,4-dione, 3-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1,8,8-trimethyl-, (1R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 947736-35-8 HCPLUS

CN 2,5-Pyrrolidinedione, 1-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 6 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:959460 HCPLUS

DOCUMENT NUMBER: 147:355843

TITLE: Method for determining purity of 3,5-disubstituted oxazolidone compounds

INVENTOR(S): Wang, Ying; Zhu, Jin; Liu, Jinsong; Lu, Tao

PATENT ASSIGNEE(S): Sichuan Beilike Biotechnology Co., Ltd., Peop. Rep. China

SOURCE: Faming Zhanli Shenqing Gongkai Shuomingshu, 30pp.

DOCUMENT TYPE: Patent

LANGUAGE: Chinese


10536687

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101021511	A	20070822	CN 2007-10088395	20070319
PRIORITY APPLN. INFO.:			CN 2007-10088395	20070319
AB The title method is characterized by employing UV detector with detection wavelength of 200-300 nm, reverse phase column with column temperature of 20-50°, and a mixture of water and 30-90% of polar organic solvent (acetonitrile, methanol, ethanol, THF, chloroform, and/or isopropanol) as mobile phase. The method is simple and rapid, and has high stability and wide application.				
IT 556801-57-1 947736-32-5 947736-33-6 947736-35-8 RL: ANT (Analyte); ANST (Analytical study) (method for determination of purity of 3,5-disubstituted oxazolidone compds.)				
RN 556801-57-1 HCPLUS CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)				


Absolute stereochemistry.



RN 947736-32-5 HCPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 947736-33-6 HCAPLUS

CN 3-Azabicyclo[3.2.1]octane-2,4-dione, 3-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1,8,8-trimethyl-, (1R,5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 947736-35-8 HCAPLUS

CN 2,5-Pyrrolidinedione, 1-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 7 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20071951312 HCPLUS
 DOCUMENT NUMBER: 147:350531
 TITLE: Method for dissolving 3,5-disubstituted oxazolidone compounds
 INVENTOR(S): Wang, Ying; Zhu, Jin; Liu, Jingsong; Lu, Tao
 PATENT ASSIGNEE(S): Sichuan Beiliike Biotechnology Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhanli Shenqing Gongkai Shuomingshu, 22pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101019825	A	20070822	CN 2007-10088394	20070319
PRIORITY APPLN. INFO.:			CN 2007-10088394	20070319
AB The method includes dissolving 3,5-disubstituted oxazolidone compds. 1 weight part in acidic solvent 0.1-100 weight part at 15-80° (pH ≤ 3.5). The acidic solvent includes formic acid, acetic acid, hydrochloric acid, sulfuric acid, oxalic acid, citric acid, etc. The method has the advantages of high specificity and low cost.				
IT 948904-05-0	948904-06-1	948904-07-2		
948904-08-3				
RL: PEP (Physical, engineering or chemical process); PROC (Process) (method for dissolving 3,5-disubstituted oxazolidone compds.)				
RN 948904-05-0	HCPLUS			
CN 1H-Isoindole-1,3(2H)-dione, 2-[(5R)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)				

10536687


Absolute stereochemistry.



RN 948904-06-1 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-(phenylmethyl)-1-piperazinyl)phenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 948904-07-2 HCPLUS

CN 3-Azabicyclo[3.2.1]octane-2,4-dione, 3-[(5R)-3-[3-fluoro-4-(4-(phenylmethyl)-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1,8,8-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 948904-08-3 HCPLUS

CN 2,5-Pyrrolidinedione, 1-[(5R)-3-[3-fluoro-4-(4-phenylimethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinylmethyl- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 8 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:840788 HCPLUS

DOCUMENT NUMBER: 147:406753

TITLE: Synthesis and antibacterial activity of oxazolidinones containing triazolyl group

AUTHOR(S): Fan, Houxing; Xu, Gang; Chen, Yilang; Jiang, Zhiteng; Zhang, Shuhua; Yang, Yushe; Ji, Ruyun


CORPORATE SOURCE: State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, 201203, Peop. Rep. China

SOURCE: European Journal of Medicinal Chemistry (2007), 42(8),

1137-1143

CODEN: EJMCA5; ISSN: 0223-5234

PUBLISHER: Elsevier Masson SAS
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 147:406753
 GI



AB A new series of oxazolidinones, e.g., I, containing triazolyl group has been synthesized and tested for in vitro antibacterial activity by MIC determination against a panel of resistant and susceptible Gram-pos. organisms. Most of the analogs in this series displayed activity superior to linezolid and vancomycin in vitro. Further, in vivo efficacies of the selected oxazolidinones were also disclosed herein.


IT 897655-35-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, antibacterial activity, and SAR of triazolyloxazolidinone derivs.)

RN 897655-35-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(3-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 897655-34-4P 897655-37-7P 897655-38-8P
 897655-39-9P 897655-41-3P 897655-42-4P
 897655-43-5P 897655-44-6P 897655-45-7P
 897655-46-8P 897655-47-9P 897655-51-5P
 897655-52-6P 897655-54-8P 897655-55-9P
 897655-56-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, antibacterial activity, and SAR of triazolyloxazolidinone derivs.)

RN 897655-34-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-37-7 HCPLUS

CN 2-Oxazolidinone, 3-[4-[4-[(4-bromophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-38-8 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(phenylsulfonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Updated Search

10536687


Absolute stereochemistry.



RN 897655-39-9 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[(3-aminophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 897655-41-3 HCAPLUS


CN 2-Oxazolidinone, 3-[3-fluoro-4-[(2-nitrophenyl)sulfonyl]-1-

10536687


piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 897655-42-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-thienylsulfonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-43-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(4-nitrophenyl)sulfonyl]l-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-44-6 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(4-methoxyphenyl)sulfonyl]l-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-45-7 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[4-[(4-chlorophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-46-8 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(4-fluorophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Updated Search

10536687


Absolute stereochemistry.



RN 897655-47-9 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(3-(trifluoromethyl)phenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




10536687


RN 897655-51-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[(2,4-difluorophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 897655-52-6 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(3-fluorophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-54-8 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(trifluoromethyl)phenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-55-9 HCAPLUS

CN Benzonitrile, 4-[(4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl)sulfonyl]- (CA INDEX NAME)

10536687



Absolute stereochemistry.



RN 897655-56-0 HCAPLUS


CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(2-(trifluoromethyl)phenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 859445-56-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation, antibacterial activity, and SAR of triazolo[1,2-a]oxazolidinone
 derivs.)
 RN 859445-56-0 HCPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-
 1-ylmethyl)-3-oxazolidinyl]phenyl]-, phenylmethyl ester (CA INDEX NAME)



Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:769790 HCPLUS
 DOCUMENT NUMBER: 148:517697
 TITLE: Preparation of substituted thio-piperidino phenyloxazolidinones having antimicrobial activity
 INVENTOR(S): Patil, Vijaykumar Jagdishwar; Patel, Mahesh Vithalbhai
 PATENT ASSIGNEE(S): Wockhardt Limited, India
 SOURCE: Indian Pat. Appl., 103pp.
 CODEN: INXXBQ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01200	A	20070629	IN 2005-MU1200	20050927
PRIORITY APPLN. INFO.:			IN 2005-MU1200	20050927



AB Title compds. I [X and Y independently = CH, CF, CCl or N; R1 = alkylsulfonyloxy, , (un)substituted alkylamido, thioalkylamido, heteroaryl or NHR4; wherein R4 = CN, COORa, CSORa, CONRbRc or CSNRbRc; wherein Ra = (un)substituted alkyl, cycloalkyl or heterocyclyl; Rb and Rc = (un)substituted alkyl, 3- to 6-membered cycloalkyl or Rb and Rc together form a 5- to 6-membered cycloalkyl or heterocyclyl ring; R2 = H, CH3, OH, halo or OCOR5, wherein R5 = (un)substituted alkyl, 5- to 6-membered cycloalkyl, aryl, heteroaryl or aralkyl; W = absent, CH2 or pyridyl; a = double bond or single bond; Q = S, SO or SO2; R3 = H, CN, alkylcarbonyl, (un)substituted alkyl, alkenyl, alkylcarbonyl, aryl, heteroaryl, cycloalkyl, substituted cycloalkyl or heterocyclyl, and their pharmaceutically acceptable salts, are prepared and disclosed having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, e.g., II was prepared from reacting (S)-N-[3-[4-(4-hydroxy-4-[(methylsulfonyloxy)methyl]piperidin-1-yl]-3-fluorophenyl]-2-oxazolidin-5-yl]methyl]ethanamide with. Selected I showed antibacterial activity with MIC value of ranging from 0.5 to 8 mcg/mL for MSSA-25923 strain.

IT 1021897-60-8P 1021897-61-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted thio-piperidino phenyloxazolidinones as antimicrobials)

RN 1021897-60-8 HCPLUS


CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-(phenylthio)-1-piperidinyl]phenyl]-5-(2H-1,2,3-triazol-2-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1021897-61-9 HCPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(4-(phenylthio)-1-piperidinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



IT 1021898-27-0 1021898-28-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of substituted thio-piperidino phenyloxazolidinones as
 antimicrobials)
 RN 1021898-27-0 HCPLUS
 CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-[(methylsulfonyl)oxy]-1-piperidinyl]phenyl]-5-(2H-1,2,3-triazol-2-ylmethyl)-, (5S)- (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 1021898-28-1 HCPLUS


CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(methylsulfonyl)oxy]-1-piperidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

L7 ANSWER 10 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:228628 HCPLUS
 DOCUMENT NUMBER: 146:441755
 TITLE: Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones
 AUTHOR(S): Phillips, Oludotun A.; Udo, Edet E.; Ali, Ahmed A. M.; Samuel, Santhosh M.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Safat, 13110, Kuwait
 SOURCE: European Journal of Medicinal Chemistry (2007), 42(2), 214-225
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:441755
 GI



AB A series of arylcarbonyl- and arylsulfonyl-piperazinyl 5-triazolylmethyl oxazolidinones were synthesized and tested against a panel of Gram-pos. and Gram-neg. bacterial clin. isolates. The arylcarbonyl oxazolidinone derivs., e.g., I, showed strong *in vitro* antibacterial activity against susceptible and resistant Gram-pos. pathogenic bacteria and were more active than the arylsulfonyl derivs. Substitution of varied electron-withdrawing and electron-donating groups on the Ph ring in the arylcarbonyl series did not alter antibacterial activity significantly. However, in the arylsulfonyl series, Me substitution on the Ph ring resulted in the loss of antibacterial activity. Antibacterial activity could not be directly correlated with the calculated partition coefficient (*Clog P*) values in this series of compds.

IT 897655-34-4P 897655-38-8P 897655-42-4P
 934686-73-4P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, anti bacterial activity and SAR of [(arylsulfonylpiperazine)phenyl](triazolylmethyl)oxazolidinones via amidation of (piperazinephenyl)(triazolylmethyl)oxazolidinones with arylsulfonyl chlorides)

RN 897655-34-4 HCPLUS

10536687

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-38-8 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(phenylsulfonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10536687

RN 897655-42-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-thienylsulfonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 934686-73-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(3-methylphenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 371195-29-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation, anti bacterial activity and SAR of
[(arylsulfonylpiperazine)phenyl](triazolylmethyl)oxazolidinones via


10536687

amidation of (piperazinephenyl)(triazolymethyl)oxazolidinones with arylsulfonyl chlorides)

RN 371195-29-8 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 859445-55-9P 934686-50-7P 934686-51-8P
934686-52-9P 934686-53-0P 934686-54-1P
934686-55-2P 934686-56-3P 934686-57-4P
934686-58-5P 934686-59-6P 934686-60-9P
934686-61-0P 934686-62-1P 934686-63-2P
934686-64-3P 934686-65-4P 934686-66-5P
934686-67-6P 934686-68-7P 934686-69-8P
934686-70-1P 934686-71-2P 934686-72-3P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, antibacterial activity and SAR of
[(arylcarbonylpiperazine)phenyl](triazolymethyl)oxazolidinones via
amidation of (piperazinephenyl)(triazolymethyl)oxazolidinone with
arylcarbonyl chlorides)

RN 859445-55-9 HCAPLUS

CN 2-Oxazolidinone, 3-[4-(4-benzoyl-1-piperazinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687





RN 934686-50-7 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-(4-(2-phenylacetyl)-1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 934686-51-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-(2-chlorobenzoyl)-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 934686-52-9 HCPLUS
CN 2-Oxazolidinone, 3-[4-[4-(4-chlorobenzoyl)-1-piperazinyl]-3-fluorophenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 934686-53-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-fluorobenzoyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A



PAGE 2-A




RN 934686-54-1 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(3-fluorobenzoyl)-1-piperazinyl]phenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A





PAGE 2-A





RN 934686-55-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(4-fluorobenzoyl)-1-piperazinyl]phenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 934686-56-3 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-nitrobenzoyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 934686-57-4 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(3-nitrobenzoyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 934686-58-5 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(4-nitrobenzoyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 934686-59-6 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-methylbenzoyl)-1-piperazinyl]phenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A





PAGE 2-A



RN 934686-60-9 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(3-methylbenzoyl)-1-piperazinyl]phenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 934686-61-0 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(4-methylbenzoyl)-1-piperazinyl]phenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A



PAGE 2-A




RN 934686-62-1 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-methoxybenzoyl)-1-piperazinyl]phenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A



PAGE 2-A




RN 934686-63-2 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(3-methoxybenzoyl)-1-piperazinyl]phenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A





PAGE 2-A



RN 934686-64-3 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(4-methoxybenzoyl)-1-piperazinyl]phenyl]-
5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 934686-65-4 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-[(2E)-1-oxo-3-phenyl-2-propen-1-yl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

10536687




RN 934686-66-5 HCPLUS

CN 2-Oxazolidinone, 3-[4-[(2E)-3-(2-chlorophenyl)-1-oxo-2-propen-1-yl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



10536687


PAGE 2-A




RN 934686-67-6 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(3-pyridinylcarbonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 934686-68-7 HCPLUS


Updated Search

10536687


CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(4-pyridinylcarbonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 934686-69-8 HCPLUS

CN 2-Oxazolidinone, 3-[4-[4-[(2-chloro-3-pyridinyl)carbonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 934686-70-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-furanylcarbonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 934686-71-2 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-thienylcarbonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 934686-72-3 HCPLUS

CN 1,2-Ethanedione, 1-[4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl]-2-(2-thienyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:226910 HCPLUS
 DOCUMENT NUMBER: 146:295903
 TITLE: Preparation of oxazolidinones possessing antimicrobial activity and pharmaceutical compositions thereof
 INVENTOR(S): Sindkhedkar, Milind D.; Bhavsar, Satish B.; Patil, Vijaykumar J.; Deshpande, Prasad K.; Patel, Mahesh V.
 PATENT ASSIGNEE(S): Sindkhedkar, Milind, D., India; Bhavsar, Satish, B.; Patil, Vijaykumar, J.; Deshpande, Prasad, K.; Patel, Mahesh, V.
 SOURCE: PCT Int. Appl., 210 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007023507	A2	20070301	WO 2006-IN208	20060619
WO 2007023507	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
IN 2005MU00723	A	20070706	IN 2005-MU723	20050620
EP 1912980	A2	20080423	EP 2006-821680	20060619
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:

IN 2005-MU723



A 20050620

OTHER SOURCE(S):
GI

MARPAT 146:295903

WO 2006-IN208

W 20060619



AB Title compds. I [R1 = OH, formamide, (un)substituted amine, etc.; X and Y independently = CH, CF or N; Q = (un)substituted heterocyclyl, heteroaryl, aryl, etc.], and their pharmaceutically acceptable salts, were prepared and disclosed as having antimicrobial activity. Thus, e.g., II was prepared by reduction of the corresponding oxopiperidine derivative (preparation given).

Several

microbial assays are described, e.g., selected I displayed antibacterial activity for *Staphylococcus aureus* ATCC 25923 equal to 0.5 to \geq 8 mg/mL. Thus, the present invention provides novel oxazolidinone derivs., processes for making compds. as well as antimicrobial pharmaceutical compns. containing said derivs. as active ingredients and methods of treating microbial infections with the said derivs.



IT 928158-79-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolidinones possessing antimicrobial activity and pharmaceutical compns. thereof)

RN 928158-79-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[5-methyl-6-(4-thiomorpholinyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 928157-54-4P 928157-57-7P 928158-93-4P
928159-13-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of oxazolidinones possessing antimicrobial activity and pharmaceutical compns. thereof)

RN 928157-54-4 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 928157-57-7 HCPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[3-fluoro-4-(1H-1,2,3-triazol-1-yl)-1-piperidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 928158-93-4 HCPLUS



CN 2-Oxazolidinone, 3-[3-fluoro-4-[5-methyl-6-(1-oxido-4-thiomorpholinyl)-3-pyridinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 928159-13-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[6-(1,1-dioxido-4-thiomorpholinyl)-5-methyl-3-pyridinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 928160-34-3 928160-36-5 928160-50-3
928160-64-9 928160-65-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolidinones possessing antimicrobial activity and pharmaceutical compns. thereof)

RN 928160-34-3 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(4-azido-1-piperidinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 928160-36-5 HCPLUS

CN 2-Oxazolidinone, 3-[4-(4-azido-1-piperidinyl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 928160-50-3 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[3-fluoro-4-[(4-methylphenyl)sulfonyl]oxy]-1-piperidinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 928160-64-9 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-methylphenyl)sulfonyl]oxy]-1-(2-(4-fluorophenyl)piperidinyl)-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 928160-65-0 HCPLUS

Updated Search

CN 4-Piperidineacetonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 12 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:753777 HCPLUS

DOCUMENT NUMBER: 145:271783

TITLE: Preparation of 5-(1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one derivatives for treatment of infection

INVENTOR(S): Yang, Yushe; Fan, Houxing; Chen, Kaixian; Ji, Ruyun
PATENT ASSIGNEE(S): Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Peop. Rep. China; Nanjing Changao Pharmaceutical Science and Technology Co., Ltd.

SOURCE: Faming Zhanli Shengqing Gongkai Shuomingshu, 51 pp.
CODEN: CNXEV

DOCUMENT TYPE: Patent
LANGUAGE: Chinese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1807427	A	20060726	CN 2006-10023990	20060220
WO 2007095784	A1	20070830	WO 2006-CN662	20060413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: CN 2006-10023990 A 20060220
 OTHER SOURCE(S): MARPAT 145:271783
 GI



AB The title triazole derivs. I [wherein n = 1-3; m = 1-2; R1 and R2 = independently H or F; R3 = (un)substituted alkyl or (hetero)aryl] or pharmaceutically acceptable salts thereof were prepared for the treatment of infection (no data). For example, (5R)-3-[3-fluoro-4-(piperazin-1-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one hydrochloride was reacted with 3-furancarboxaldehyde in DMF in the presence of formic acid to give II (55.2%). II showed anti-infective activity with MIC₅₀ of 0.03 µg/mL against staphylococcus aureus.



IT 907594-52-9P 907594-53-0P 907594-54-1P
 907594-71-2P 907594-72-3P 907594-75-6P
 907594-83-6P 907594-87-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of 5-(1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one derivs. for treatment of infection)

RN 907594-52-9 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-nitrophenyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 907594-53-0 HCAPLUS



CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(3-nitrophenoxy)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 907594-54-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(2-nitrophenyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907594-71-2 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[[4-(phenylmethoxy)phenyl]methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 907594-72-3 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-[(3-phenylmethoxy)phenyl]methyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 907594-75-6 HCAPLUS

CN Benzaldehyde, 4-[{4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl}methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 907594-83-6 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-hydroxymethyl)phenyl]methyl]-1-piperazinylphenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687

PAGE 1-A





PAGE 2-A



RN 907594-87-0 HCAPLUS

CN Benzaldehyde, 3-[{4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl}- (CA INDEX NAME)

Absolute stereochemistry.



IT 907594-55-2P 907594-56-3P 907594-57-4P
 907594-58-5P 907594-59-6P 907594-60-9P
 907594-61-0P 907594-62-1P 907594-63-2P
 907594-64-3P 907594-65-4P 907594-66-5P
 907594-67-6P 907594-68-7P 907594-69-8P
 907594-70-1P 907594-73-4P 907594-74-5P
 907594-76-7P 907594-77-8P 907594-78-9P
 907594-79-0P 907594-80-3P 907594-81-4P
 907594-82-5P 907594-84-7P 907594-85-8P
 907594-86-9P 907594-88-1P 907594-89-2P
 907594-90-5P 907594-91-6P 907594-92-7P
 907594-93-8P 907594-94-9P 907594-95-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of 5-(1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one derivs. for treatment of infection)

RN 907594-55-2 HCPLUS


CN 2-Oxazolidinone, 3-[4-[4-[(4-aminophenyl)methyl]-1-piperazinyl]-3-

10536687


fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 907594-56-3 HCPLUS



CN 2-Oxazolidinone, 3-[4-[(3-aminophenyl)methyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 907594-57-4 HCPLUS
 CN 2-Oxazolidinone, 3-[4-[4-[(2-aminophenyl)methyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907594-58-5 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-furanyl methyl)-1-piperazinyl]phenyl]-
 5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687


RN 907594-59-6 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(3-furanyl methyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907594-60-9 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(5-methyl-2-furanyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 907594-61-0 HCPLUS
CN 2-Oxazolidinone, 3-[4-[4-[(5-chloro-2-furanyl)methyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 907594-62-1 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-thienylmethyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 907594-63-2 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(3-thienylmethyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 907594-64-3 HCPLUS

CN 2-Oxazolidinone, 3-[4-[4-[(5-bromo-2-thienyl)methyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Updated Search

10536687


Absolute stereochemistry.



RN 907594-65-4 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-{4-[(3-methyl-2-thienyl)methyl]-1-piperazinyl}phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 907594-66-5 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-{4-[(5-methyl-2-thienyl)methyl]-1-piperazinyl}phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

10536687




RN 907594-67-6 HCPLUS


CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-pyridinylmethyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




Updated Search

10536687


RN 907594-68-7 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(4-pyridinylmethyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A




RN 907594-69-8 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(3-pyridinylmethyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907594-70-1 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(5-nitro-2-furanyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




10536687


RN 907594-73-4 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(4-hydroxyphenyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A





RN 907594-74-5 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(3-hydroxyphenyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 907594-76-7 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[(dimethylamino)methyl]phenyl]methyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 907594-77-8 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-[4-[(diethylamino)methyl]phenyl]methyl]-1-piperazinyl-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907594-78-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[[4-[(1-pyrrolidinylmethyl)phenyl]methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




10536687


RN 907594-79-0 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(1-piperidinylmethyl)phenyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 907594-80-3 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(4-morpholinylmethyl)phenyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 907594-81-4 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-[4-(4-thiomorpholinylmethyl)phenyl]methoxy]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 907594-82-5 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 907594-84-7 HCAPLUS



CN Benzaldehyde, 4-[{4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl}methyl]-, 1-oxime (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 907594-85-8 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[(acetyloxy)methyl]phenyl]methyl]-1-piperazinyl-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 907594-86-9 HCAPLUS

CN Benzaldehyde, 4-[{4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl}methyl]-, 1-hydrazone (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

10536687

PAGE 1-A





PAGE 2-A





RN 907594-88-1 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[(3-[(dimethylamino)methyl]phenyl)methyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 907594-89-2 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[(3-[(diethylamino)methyl]phenyl)methyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907594-90-5 HCPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-[(3-(1-pyrrolidinylmethyl)phenyl)methyl]-1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




10536687


RN 907594-91-6 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(3-(1-piperidinylmethyl)phenyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A





RN 907594-92-7 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(3-[(4-methyl-1-piperazinyl)methyl]phenyl)methyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907594-93-8 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-morpholinylmethyl)phenyl]methyl]-1-piperazinylphenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 907594-94-9 HCAPLUS



CN Benzaldehyde, 3-[{4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl}methyl]-, 1-oxime (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 907594-95-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-[(3-hydroxymethyl)phenyl]methyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 13 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:382866 HCAPLUS
 DOCUMENT NUMBER: 144:432790
 TITLE: Preparation of oxazolidinone derivatives as antimicrobials
 INVENTOR(S): Mehta, Anita; Das, Biswajit; Rudra, Sonali; Yadav, Ajay Singh; Kumari, Sangita; Salman, Mohammad; Rattan, Ashok
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2006043121	A1	20060427	WO 2004-IB3439	20041020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: WO 2004-IB3439 20041020
 OTHER SOURCE(S): CASREACT 144:432790; MARPAT 144:432790
 GI



AB Title compds. such as I [wherein R1 = (un)substituted amine, hydroxy, thioalkyl, etc.; U = H, (un)substituted alkyl, F, etc.; Q = O, S or (alkyl)N; G = H, alkyl, CN, etc.; n = 0-3; and pharmaceutically acceptable salts, solvates, esters, polymorphs, enantiomers, diastereomers, N-oxides, prodrugs or metabolites thereof] were prepared as antimicrobial agents. For example, II was provided in a multi-step synthesis starting from tert-Bu 4-[2-fluoro-4-[(5R)-5-[(methylsulfonyl)oxy]methyl]-2-oxo-1,3-oxazolidin-3-yl]phenyl]piperazine-1-carboxylate. I showed antimicrobial activity with MIC of 16 µg/mL against ATCC 25923, 8 µg/mL against ATCC 29212, and etc. Thus, I are useful as antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-pos. aerobic bacteria, such as multiple-resistant staphylococci and streptococci as well as anaerobic organisms, such as Clostridia spp. species, and acid fast organisms.

IT 885013-13-8


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolidinone derivs. as antimicrobials)

RN 885013-13-8 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5S)-2-oxo-5-[(2-oxo-1(2H)-pyridinyl)methyl]-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

10536687

Absolute stereochemistry.




IT 885013-14-9P, tert-Butyl 4-[4-[(5S)-5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]-2-fluorophenyl]piperazine-1-carboxylate 885013-15-0P, tert-Butyl 4-[2-fluoro-4-[(5R)-5-[(1H-imidazol-1-yl)methyl]-2-oxo-1,3-oxazolidin-3-yl]phenyl]piperazine-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolidinone derivs. as antimicrobials)

RN 885013-14-9 HCPLUS


CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 885013-15-0 HCPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-5-(1H-imidazol-1-ylmethyl)-2-oxo-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:317385 HCPLUS
 DOCUMENT NUMBER: 144:370098
 TITLE: Oxazolidinone derivatives, particularly benzoxadiazole phenyloxazolidinones, useful as antimicrobials, and processes for their preparation, pharmaceutical compositions containing them, and methods of their use for treating microbial infections
 INVENTOR(S): Das, Biswajit; Rudra, Sonali; Salman, Mohammad; Rattan, Ashok
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006035283	A1	20060406	WO 2005-IB2840	20050926

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,



LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2004-DE1843 A 20040927

OTHER SOURCE(S): CASREACT 144:370098; MARPAT 144:370098

GI



AB The invention relates to substituted phenyloxazolidinones I and processes for their preparation [wherein: R1 is ORj, SRj, NHY1Rf, NRfRg, heterocyclic or heteroaryl; Rj is H, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, heteroarylalkyl or heterocyclalkyl; Y1 is CO, C(:S) or SO2; Rf is H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclalkyl; Rg is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclalkyl; U and V are each independently H, lower (C1-6)alkyl or halo; Y and W are each independently no atom, O, CH2, CO, CH2NH, NHCH2, CH2NHCH2, CH2N(R11)CH2, CH2(Re)N, CH(R11), S, CH2(CO), NH, NRe, (CO)CH2, N(Re)CON(Re), N(Re)C(S)N(Re), SO2 or SO; R11 is optionally substituted C1-2 alkyl, C3-12 cycloalkyl, C1-6 alkoxy, C1-6 alkyl, C1-6-alkylcarbonyl, C1-6-alkylcarboxy, aryl or heteroaryl; Re is H, optionally substituted C1-12 alkyl, C3-12 cycloalkyl, C1-6 alkoxy, C1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkylcarboxy, aryl or heteroaryl; and A is bond, piperidine-1,4-diyl with optional addnl. 4-thio or 4-oxy and/or 3,5-(CH2)0-2, piperazine-1,4-diyl, furandiyil, pyrrolediyl, thiophenediyl, pyridinediyl; X is CH, CH-S, CH-O or N; Q is O, N or S; n is 0-1; including pharmaceutically acceptable salts, solvates, enantiomers, diastereomers or polymorphs]. The invention also relates to pharmaceutical compns. comprising I. I are useful as antimicrobial agents, and can be particularly effective against a number of human and

veterinary pathogens, including gram-pos. aerobic bacteria (e.g., multiple-resistant staphylococci, streptococci and enterococci), anaerobic organisms (e.g., *Bacteroides* spp. and *Clostridia* spp.), and acid-fast organisms (e.g., *Mycobacterium tuberculosis*, *Mycobacterium avium*, and *Mycobacterium* spp.). Fourteen compds. were prepared, and are also claimed by name. For instance, coupling of 5-bromo-2,1,3-benzoxadiazole with N-[(5S)-3-[3-fluoro-4-(trimethylstannyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methylacetamide in the presence of Et3N and Pd(PPh₃)₂C12 in DMF at 100°, gave invention compound II. The activity of I was comparable or superior to linezolid against a wide variety of organisms. For instance, against vancomycin-resistant Enterococci ATCC 6A, the MIC of I was in some cases between 0.25 and 4 µg/mL, vs. 2 µg/mL for linezolid. Against Enterococcus faecalis 303, the MIC of I was 0.124 to 4 µg/mL, vs. 16 µg/mL for linezolid.


IT 371195-29-8P, tert-Butyl 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]piperazine-1-carboxylate
882185-07-1P, tert-Butyl 4-[2-fluoro-4-[(5R)-2-oxo-5-(2H-1,2,3-triazol-2-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]piperazine-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of benzoxadiazole-substituted phenyloxazolidinones as antimicrobials)

RN 371195-29-8 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 882185-07-1 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(2H-1,2,3-triazol-2-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:314790 HCPLUS
 DOCUMENT NUMBER: 145:124543
 TITLE: Method for preparation and application of novel oxazolidinone derivatives
 INVENTOR(S): Yang, Yushe; Xu, Gang; Ji, Ruyun; Li, Zhan; Huang, Haiyan
 PATENT ASSIGNEE(S): Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Peop. Rep. China
 SOURCE: Faming Zhanli Shenqing Gongkai Shuomingshu, 44 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1749256	A	20060322	CN 2004-10066453	20040916
CN 100360525	C	20080109		
PRIORITY APPLN. INFO.:			CN 2004-10066453	20040916
OTHER SOURCE(S):			CASREACT 145:124543; MARPAT 145:124543	
GI				



AB This invention relates to novel oxazolidone derivs. for treating infection disease shown as compound I (R1 = H, F; R2 = H, F; R3 = alkyl sulfonyl, aryl sulfonyl, aryl heterocyclic sulfonyl, alkyloxy carbonyl, aryl alkylloxy carbonyl, alkyl carbonyl and substituted). The title oxazolidone derivs. are prepared by reacting 3,4-difluoronitrobenzene or 3,4,5-trifluoro nitrobenzene in non-protonic solvent to give piperazylfluorobenzene; catalytic hydrogenation to get the corrsponding aniline; protecting the amino group with carbobenzoxy formyl chloride (CBZ); reacting with (R)-glycidylbutyrate in THF or ether to provide an important intermediate II; methylsulfonation the hydroxy group and reacting with sodium azide , further reacting with acetylene to form triazole ring; deprotecting CBZ group by catalytic hydrogenation in the presence of catalyst Pd, Ni, Rh and reacting with acid chloride to obtain the title product. The title oxazolidone derivative comprises (5R)-3-(3-fluoro-4-(N-1-(4-tetrabutoxy carbonylpiperazine-yl)phenyl)-5-(1,2,3-triazole-1-methyl)oxazolidine-2-one etc. and can be used as antibacterial agent for treating infection disease.

IT 859445-56-0P 897655-35-5P 897655-43-5P

897655-49-1P 897655-57-1P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of oxazolidone derivs. as antibacterial agent)

RN 859445-56-0 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, phenylmethyl ester (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 897655-35-5 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(3-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-43-5 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Updated Search

10536687


Absolute stereochemistry.



RN 897655-49-1 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[2-(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-57-1 HCAPLUS

10536687

CN 1-Piperazinecarboxylic acid, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 371195-29-8P 859445-47-9P 859445-49-1P
897655-34-4P 897655-36-6P 897655-37-7P
897655-38-8P 897655-39-9P 897655-40-2P
897655-41-3P 897655-42-4P 897655-44-6P
897655-45-7P 897655-46-8P 897655-47-9P
897655-48-0P 897655-50-4P 897655-51-5P
897655-52-6P 897655-53-7P 897655-54-8P
897655-55-9P 897655-56-0P 897655-59-3P
897655-60-6P 897655-61-7P 897655-62-8P
897655-63-9P 897655-64-0P 897655-65-1P
897655-66-2P 897655-67-3P 897655-68-4P
897655-69-5P 897655-70-8P 897655-71-9P
897655-72-0P 897655-73-1P 897655-74-2P
897655-75-3P 897655-76-4P 897655-77-5P
897655-78-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(synthesis of oxazolidone derivs. as antibacterial agent)

RN 371195-29-8 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 859445-47-9 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(methylsulfonyl)-1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-49-1 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.

Updated Search



RN 897655-34-4 HCAPLUS
 CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-36-6 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, methyl ester (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 897655-37-7 HCPLUS

CN 2-Oxazolidinone, 3-[4-[(4-bromophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-38-8 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(phenylsulfonyl)-1-piperazinyl]phenyl]-5-

10536687

(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-39-9 HCPLUS

CN 2-Oxazolidinone, 3-[4-[4-[(3-aminophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687



RN 897655-40-2 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2-methylpropyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 897655-41-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(2-nitrophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-42-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-thienylsulfonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-44-6 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-[(4-methoxyphenyl)sulfonyl]l-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-45-7 HCPLUS

CN 2-Oxazolidinone, 3-[4-[4-[(4-chlorophenyl)sulfonyl]l-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-46-8 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-fluorophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 897655-47-9 HCAPLUS


CN 2-Oxazolidinone, 3-[3-fluoro-4-[(3-(trifluoromethyl)phenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX

Updated Search

10536687

NAME)


Absolute stereochemistry.



RN 897655-48-0 HCPLUS

CN 2-Oxazolidinone, 3-[4-[(4-aminophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687



RN 897655-50-4 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2-hydroxyacetyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 897655-51-5 HCAPLUS
CN 2-Oxazolidinone, 3-[4-[4-[(2,4-difluorophenyl)sulfonyl]-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-52-6 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-((3-fluorophenyl)sulfonyl)piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-53-7 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(trifluoromethoxy)phenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-54-8 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(trifluoromethyl)phenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX

10536687

NAME)


Absolute stereochemistry.



RN 897655-55-9 HCPLUS

CN Benzonitrile, 4-[(4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.




10536687


RN 897655-56-0 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(2-(trifluoromethyl)phenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 897655-59-3 HCPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-60-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 897655-61-7 HCAPLUS


CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-(3-nitrophenyl)sulfonyl]piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX

Updated Search

10536687

NAME)


Absolute stereochemistry.



RN 897655-62-8 HCPLUS

CN l-Piperazinecarboxylic acid, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-63-9 HCPLUS

Updated Search

10536687

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(4-(phenylsulfonyl)-1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-64-0 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2-methylpropyl ester (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10536687



RN 897655-65-1 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 897655-66-2 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(4-[(2-nitrophenyl)sulfonyl]-1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-67-3 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(4-nitrophenoxy)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-68-4 HCAPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-69-5 HCAPLUS

CN 2-Oxazolidinone, 3-[4-[(4-chlorophenyl)sulfonyl]-1-piperazinyl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Updated Search

10536687


Absolute stereochemistry.



RN 897655-70-8 HCPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(4-fluorophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



10536687

RN 897655-71-9 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-[[3-(trifluoromethyl)phenyl]sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 897655-72-0 HCAPLUS
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-[2-(phenylmethoxy)acetyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

10536687





RN 897655-73-1 HCPLUS

CN 2-Oxazolidinone, 3-[4-{[(2,4-difluorophenyl)sulfonyl]-1-piperaziny1}-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 897655-74-2 HCPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-[(3-fluorophenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-75-3 HCPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-[(4-(trifluoromethoxy)phenyl)sulfonyl]-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 897655-76-4 HCAPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(4-(trifluoromethyl)phenyl)sulfonyl]-1-piperazinyl]phenyl-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 897655-77-5 HCAPLUS

CN Benzonitrile, 4-[(4-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl)sulfonyl]- (CA INDEX NAME)

Updated Search

10536687



Absolute stereochemistry.



RN 897655-78-6 HCAPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[4-[(2-(trifluoromethyl)phenyl)sulfonyl]1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 16 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:465012 HCPLUS
 DOCUMENT NUMBER: 143:149749
 TITLE: Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones
 AUTHOR(S): Phillips, Oludotun A.; Udo, Edet E.; Ali, Ahmed A. M.; Samuel, Santhosh M.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, Safat, 13110, Kuwait
 SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(12), 4113-4123
 PUBLISHER: CODEN: BMECEP; ISSN: 0968-0896
 Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:149749
 AB A new series of N-linked 5-triazolylmethyl oxazolidinones with varying

substitution at the piperazine nitrogen 4-position were synthesized and tested against a panel of Gram-pos. and Gram-neg. bacteria including clin. isolates. Most of the compds. showed excellent antibacterial activity against susceptible and resistant Gram-pos. organisms. One of the compds. showed enhanced antibacterial activity against *Moraxella catarrhalis*.


IT 371195-29-8P

RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones)

RN 371195-29-8 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 859445-41-3P 859445-42-4P 859445-43-5P
 859445-44-6P 859445-45-7P 859445-46-8P
 859445-47-9P 859445-48-0P 859445-49-1P
 859445-50-4P 859445-51-5P 859445-52-6P
 859445-53-7P 859445-54-8P 859445-55-9P
 859445-56-0P


RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones)

RN 859445-41-3 HCPLUS

CN 1-Piperazinecarboxaldehyde, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 859445-42-4 HCAPLUS
CN 2-Oxazolidinone, 3-[4-(4-acetyl-1-piperazinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-43-5 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2,2,2-trifluoroacetyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.

10536687



RN 859445-44-6 HCPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(2,2,2-trichloroacetyl)-1-piperazinyl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-45-7 HCPLUS
CN 2-Oxazolidinone, 3-[4-[4-(2,2-dichloroacetyl)-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 859445-46-8 HCAPLUS

CN 1-Piperazinecarboxthioic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, S-methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-47-9 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(methylsulfonyl)-1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Updated Search

10536687


Absolute stereochemistry.



RN 859445-48-0 HCAPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-(1-oxopropyl)-1-piperazinyl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-49-1 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, ethyl ester (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 859445-50-4 HCPLUS

CN 1-Piperazinecarbothioic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, S-ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 859445-51-5 HCPLUS

CN 1,2-Propanedione, 1-[4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-

10536687

ylmethyl)-3-oxazolidinyl]phenyl]-1-piperazinyl}- (CA INDEX NAME)


Absolute stereochemistry.



RN 859445-52-6 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-{4-(2-methyl-1-oxopropyl)-1-piperazinyl}phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

10536687

RN 859445-53-7 HCPLUS
CN 2-Oxazolidinone, 3-[4-[4-(cyclopentylcarbonyl)-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 859445-54-8 HCPLUS
CN 2-Oxazolidinone, 3-[4-[4-(cyclohexylcarbonyl)-1-piperazinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 859445-55-9 HCAPLUS
 CN 2-Oxazolidinone, 3-[4-(4-benzoyl-1-piperazinyl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 859445-56-0 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.






REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:409511 HCAPLUS
 DOCUMENT NUMBER: 142:463731
 TITLE: A preparation of novel oxazolidinone derivatives,
 useful as antibacterial agents
 INVENTOR(S): Kang, Jae-Hoon; Park, Chun-Ho; Kwon, Jin-Sun
 PATENT ASSIGNEE(S): Il-Dong Pharm. Co., Ltd., S. Korea
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042523	A1	20050512	WO 2004-KR2805	20041103
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, US, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005042446	A	20050509	KR 2004-82328	20041014
PRIORITY APPLN. INFO.:			KR 2003-77372	A 20031103
			KR 2004-82328	A 20041014

OTHER SOURCE(S):
GI

CASREACT 142:463731; MARPAT 142:463731



AB The invention relates to a preparation of novel oxazolidinone derivs. of formula I (R is H, amide, aldehyde, or nitrile, etc.; each X is independently N or CH), useful as antibacterial agents. For instance, oxazolidinone derivative II [MIC (ug/mL): str. pyogenes 77A - 0.4, s. aureus 285 - 0.8, MRSA 2 - 1.6; LD50 >5000 mg/kg] was prepared via 1,3-dipolar cycloaddn. of vinyl acetate to (azidomethyl)oxazolidinone derivative III with a yield of 74%.

IT 851529-81-2P 851529-82-3P 851529-83-4P

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of novel oxazolidinone derivs. useful as antibacterial agents)

RN 851529-81-2 HCPLUS

CN 1H-Pyrrole-3-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.

10536687




RN 851529-82-3 HCPLUS

CN 1H-Pyrrole-3-carboxaldehyde, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 3-oxime (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 851529-83-4 HCPLUS

CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 851529-89-0P 851529-92-5P 851529-95-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel oxazolidinone derivs. useful as antibacterial agents)


RN 851529-89-0 HCPLUS

CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-

10536687

ylmethyl)-3-oxazolidinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 851529-92-5 HCPLUS


CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 851529-83-4

CMF C17 H13 F N6 O2

Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



Updated Search


10536687

RN 851529-95-8 HCPLUS
CN 1H-Pyrrole-3-carbonitrile, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate
(1:1) (CA INDEX NAME)

CM 1


CRN 851529-83-4
CMF C17 H13 F N6 O2

Absolute stereochemistry.



CM 2

CRN 77-92-9
CMF C6 H8 O7



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:347264 HCPLUS
DOCUMENT NUMBER: 142:404216
TITLE: Fluorescent probes for ribosomes and method of use
INVENTOR(S): Ma, Zhenkun; Li, Jing; Kim, In Ho; Jin, Yafei; Lynch, Anthony Simon; Roche, Eric; Beeman, Doug
PATENT ASSIGNEE(S): Cumbre Inc., USA
SOURCE: PCT Int. Appl., 126 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.

KIND

APPLICATION NO.

DATE

WO 2005036169	A2	20050421	WO 2004-US32196	20040930
WO 2005036169	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 20050118624	A1	20050602	US 2004-954996	20040930
PRIORITY APPLN. INFO.:			US 2003-508401P	P 20031003

OTHER SOURCE(S): MARPAT 142:404216

AB Fluorescent probes are disclosed that have binding affinity to ribosomes. The fluorescent probes are useful tools for identifying small mols. that bind to the 50S or 30S subunits of the bacterial and other ribosome inhibitors. These probes are also useful for determining the interactions between a specific ligand and the ribosome. Preparation of antibiotic-fluorophor conjugates is included.

IT 850220-41-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(fluorescent probes for ribosomes and method of use)

RN 850220-41-6 HCPLUS

CN 1H-Isindole-1,3(2H)-dione, 2-[(5S)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 19 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:182660 HCPLUS

DOCUMENT NUMBER: 142:280197

TITLE: Preparation of aryloxazolidinone derivatives as antimicrobial agents

INVENTOR(S): Gordeev, Mikhail; Wang, Qiang

PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA



SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019214	A1	20050303	WO 2004-IB2669	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536480	A1	20050303	CA 2004-2536480	20040813
EP 1660488	A1	20060531	EP 2004-744290	20040813
R: AI, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004013838	A	20061024	BR 2004-13838	20040813
JP 2007503426	T	20070222	JP 2006-524441	20040813
US 20050065187	A1	20050324	US 2004-924752	20040824
MX 2006PA02188	A	20060427	MX 2006-PA2188	20060224
PRIORITY APPLN. INFO.:			US 2003-497531P	P 20030825
			WO 2004-IB2669	W 20040813

OTHER SOURCE(S): CASREACT 142:280197; MARPAT 142:280197
 GI



AB Title compds. represented by the formula I [wherein A = isoxazolin-3,5-diyl, 2-oxazolinone-3,5-diyl, 2-furanone-3,5-diyl, 5-isoxazolinone-2,4-diyl; X = N or C; Z = oxy-isoxazolyl, (oxy)-1,2,3-triazolyl, aminocarbonylmethyl, etc.; R2-R5 = independently H,

Cl, F, Me, NH₂, or OH; L, Y = independently H, OH, F, O, NOH, NOalkyl; m, n, p = independently 0 or 1; and pharmaceutically acceptable salts thereof] were prepared as antimicrobial agents. For example, II was given in a multi-step synthesis starting from the reaction of 1,2,3,6-tetrahydropyridine with 3,4-difluoronitrobenzene. I were tested for inhibition against SAUR 9213, SPNE 9912, HINF 30063 and MC 30603 with MIC values of 0.25-64 µg/mL. Thus, I and their pharmaceutical compns. are useful as antibacterial agents for the treatment of a gram-neg. microbial infection.


IT 847256-81-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of aryloxazolidinone derivs. as antimicrobial agents)

RN 847256-81-9 HCPLUS

CN 2-Oxazolidinone, 3-[4-[(3S,4R)-3,4-dihydroxy-1-piperidinyl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 847256-82-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryloxazolidinone derivs. as antimicrobial agents)

RN 847256-82-0 HCPLUS

CN 4-Piperidinone, 1-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-hydroxy-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:58200 HCPLUS
 DOCUMENT NUMBER: 142:155957
 TITLE: Preparation of 3-aryloxazolidin-2-one derivatives as antibiotics
 INVENTOR(S): Hammond, Milton L.; Fukuda, Yasumichi
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005422	A1	20050120	WO 2004-US20738	20040629
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004256086	A1	20050120	AU 2004-256086	20040629
AU 2004256086	B2	20071206		
CA 2529294	A1	20050120	CA 2004-2529294	20040629

EP 1646630	A1	20060419	EP 2004-777200	20040629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1816547	A	20060809	CN 2004-80018955	20040629
JP 2007521284	T	20070802	JP 2006-517740	20040629
US 20070293493	A1	20071220	US 2007-559868	20070302
PRIORITY APPLN. INFO.:			US 2003-483901P	P 20030702
			US 2004-546985P	P 20040224
			WO 2004-US20738	W 20040629

OTHER SOURCE(S): CASREACT 142:155957; MARPAT 142:155957
GI



AB New oxazolidinones having a cyclopropyl moiety (I) [R1, R2 = independently H, NR5R6, CR7R8R9, C(R)2OR14, CH2NHR14, C(O)R13, C(:NOH)H, C(:NOR13)H, C(:NR13)R13, C(:NOR33)R, C(O)N(R13)2, C(O)N(R13)2, C(=NOH)N(R13)2, NH(C(:X1)N(R13)2, (C:NH)R7, N(R13)C(:X1)N(R13)2, CO2R13, SO2R14, N(R13)SO2R14, N(R13)COR14, cyano-C1-6 alkyl, cyano, CH:C(R)2, etc.; A = C, CH, N; --- represents an optional bond; ring A = aryl, heteroaryl, heterocyclic; Rx = H, Cl-6 alkyl; R3 = (un)substituted aromatic heterocyclic group containing at least one nitrogen in the ring which is attached through a bond on any N; R4, R4a = H, halogen, Cl-6 alkoxy, Cl-6 alkyl; r, s = 1-3, provided that r+s≤4; R5, R6 = H, each (un)substituted Cl-6 alkyl, Cl-6 acyl, or Cl-6 alkylsulfonyl, etc.; R7 = H, halo, cyano, CO2R, CON(R)2, CHO, CH2NHAc, C(:NOR), OH, Cl-6 alkoxy, Cl-6 alkyl, alkenyl, (CH2)nNH2, etc.; R8, R9 = H, cyano, each (un)substituted Cl-6 alkyl or Ph; X1 = O, S, NR13, NCN, NCO2R16, or NSO2R14; R13 = H, Cl-6 alkyl, C6-10]

aryl, NR5R6, SR8, S(O)R8, S(O)2R8, cyano, OH, Cl-6 alkoxy carbonyl, CO2H, etc.; R14 = amino, Cl-6 alkyl, Cl-6 haloalkyl, (un)substituted Ph, etc.; R15 = Cl-6 alkyl or (un)substituted benzyl; m, n, p, q = 0, 1], enantiomers, diastereomers, or pharmaceutically acceptable salts, hydrates, or prodrugs thereof are prepared. These compds. are effective as antibacterial agents against aerobic and anaerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides sp., Clostridia sp., as well as acid-fast organisms such as Mycobacterium tuberculosis and other mycobacterial species. They are coadministered with vitamin B2, vitamin B4, vitamin B12, or folic acid to prevent or treat oxazolidinone-associated side effect such as normocytic anemia, peripheral sensory neuropathy, sideroblastic anemia, peripheral sensory neuropathy, optic neuropathy, seizures, thrombocytopenia, cheilosis, hypo-regenerative anemia, megaloblastic anemia and seborrheic dermatitis. Thus, (R)-5-azidomethyl-3-[4-[(1a,5a,6a)-6-(tert-butoxycarbonylamino)-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]oxazolidin-2-one (370 mg) and 2,5-norbornadiene (891 mg) in dioxane (65 mL) was heated at 70° for 6 h, and then concentrated in vacuo. A suspension of the residue in diethylene glycol di-Me ether (18.5 mL) was heated at 140° for 10 min to give 1-[(5R)-3-[4-[(1a,5a,6a)-6-(tert-butoxycarbonylamino)-3-azabicyclo[3.1.0]hexan-3-yl]-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]-1,2,3-triazole which was treated with 12 N HCl/MeOH at room temperature for

10.5

h to give, after workup, compound (II) (X = H). II (X = F) showed min. inhibitory concentration of 0.25, 0.25, 1, and 1 µg/mL against methicillin-resistant Staphylococcus aureus, penicillin- and quinolone-resistant *S. pneumoniae*, *S. pyogenes* IID692, vancomycin- and quinolone-resistant Enterococcus faecium, and *Moraxella catarrhalis* ATCC2538, resp.

IT 828252-93-3P 828252-94-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryloxazolidin-2-one derivs. as antibacterial agents)

RN 828252-93-3 HCPLUS

CN 2-Oxazolidinone, 3-[4-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 828252-94-4 HCPLUS

10536687


CN 2-Oxazolidinone, 3-[4-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 828252-99-9P 828253-00-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryloxazolidin-2-one derivs. as antibacterial agents)
RN 828252-99-9 HCPLUS
CN Carbanic acid, [(1a,5a,6a)-3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 828253-00-5 HCPLUS
CN Carbanic acid, [(1a,5a,6a)-3-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-azabicyclo[3.1.0]hex-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 21 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:58198 HCPLUS

DOCUMENT NUMBER: 142:155938

TITLE: Preparation of cyclopropyl group substituted oxazolidinones as antibiotics

INVENTOR(S): Fukuda, Yasumichi

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005420	A1	20050120	WO 2004-US20737	20040629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004256085	A1	20050120	AU 2004-256085	20040629
AU 2004256085	B2	20071206		
CA 2529293	A1	20050120	CA 2004-2529293	20040629
EP 1654259	A1	20060510	EP 2004-777199	20040629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1816545	A	20060809	CN 2004-80018905	20040629
JP 2007521283	T	20070802	JP 2006-517739	20040629
US 20070203187	A1	20070830	US 2007-655840	20070122
US 20070185132	A1	20070809	US 2007-559869	20070319

PRIORITY APPLN. INFO.:

US 2003-483904P	P 20030702
US 2004-546980P	P 20040224
US 2004-546984P	P 20040224
US 2004-878637	A3 20040629
WO 2004-US20737	W 20040629

OTHER SOURCE(S):

CASREACT 142:155938; MARPAT 142:155938

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oxazolidinones I and II [wherein R1, R2 = independently H, NH₂, CH₃ and derivs., CHO and derivs., CONH₂ and derivs., SO₂H and derivs., (un)substituted heterocyclyl, etc.; Y, Z = (un)substituted arylene, heteroarylene; R1a = defined as R1 less H, V = O, H, OH, or halo; A = C or N with provisos; Rx = H, alkyl; R3 =NHC(:O)H and derivs., NH₂SO₂H and derivs., (un)substituted NH-heteroaryl, etc.; B = (CH₂)_n; n = 0-1; and their enantiomers, diastereomers, or their pharmaceutically acceptable salts, esters, hydrates or prodrugs] are effective against aerobic and anaerobic pathogens such as multi-resistant Staphylococci, Streptococci and Enterococci, Bacteroides, Clostridia, as well as acid-fast organisms such as Mycobacterium tuberculosis, and other mycobacterial species. Thus, reacting N-[(5S)-3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl]methylacetamide with bis(pinacolato)diboron, and Pd-coupling with 5-bromo-2-(1-cyanocyclopropan-1-yl)pyridine gave oxazolidinone III. The prepared oxazolidinones were tested for antibacterial activity against a variety of strains, such as *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Enterococcus faecium*. III inhibited *Staphylococcus aureus* Smith *in vitro* with a min. inhibitory concentration of 0.06 µg/mL.

IT 827628-12-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antibacterial agent; preparation of cyclopropyl-oxazolidinones as antibiotics)

RN 827628-12-6 HCPLUS

CN 2-Oxazolidinone, 3-[4-[6-(1-aminocyclopropyl)-5-fluoro-3-pyridinyl]-3,5-difluorophenyl]-5-[(4-methyl-1H-1,2,3-triazol-1-yl)methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 22 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:55213 HCAPLUS
 DOCUMENT NUMBER: 142:134582
 TITLE: Preparation of oxazolidinone antibacterials
 INVENTOR(S): Hammond, Milton L.; Fukuda, Yasumichi
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.
 SOURCE: PCT Int. Appl., 58 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005399	A1	20050120	WO 2004-US20736	20040629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004256084	A1	20050120	AU 2004-256084	20040629
AU 2004256084	B2	20071018		

CA 2529292	A1	20050120	CA 2004-2529292	20040629
EP 1656357	A1	20060517	EP 2004-777198	20040629
R: AT, BE, CH, IE, SI, LT,	DE, DK, ES, FR, LV, FI, RO, MK,	GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL, TR, BG, CZ, EE, HU, PL, SK		
CN 1816534	A	20060809	CN 2004-80018878	20040629
JP 2007521282	T	20070802	JP 2006-517738	20040629
US 20060247286	A1	20061102	US 2006-559845	20060505
IN 2008DN04135	A	20080815	IN 2008-DN4135	20080515
PRIORITY APPLN. INFO.:				
US 2003-483905P P 20030702				
US 2004-546947P P 20040224				
US 2004-553963P P 20040318				
WO 2004-US20736 W 20040629				
IN 2005-DN5722 A3 20051209				

OTHER SOURCE(S): MARPAT 142:134582
GI



AB Title compds. [I; R1 = H, NR5R6, CR7R8R9, COR13, (substituted) heterocyclyl, etc.; A = NR, O, S, SO, SO₂; Ar = (substituted) aryl, heteroaryl, heterocycl; R3 = NR13(C:X)R12, NR13SO2R14, (substituted) heteroaryl, etc.; n = 0, 1; Rx = H, alkyl; R5, R6 = H, (substituted) alkyl, acyl, heterocycl, etc.; R5R6, R7R8 = atoms to form a 3-7 membered heterocyclic ring; R7 = H, halo, cyano, CHO, OH, alkyl, alkoxy, alkenyl, etc.; R8, R9 = H, cyano, (substituted) alkyl, Ph; R13 = H, alkyl, aryl, NR5R6, cyano, OH, alkylcarbonyl, CO₂H, acyl, (substituted) (heterocyclic) ring, etc.; R14 = amino, alkyl, haloalkyl, (substituted) heterocycl, Ph; X2 = O, S, NH, NSO2R14], were prepared. Thus, 1-benzyloxycarbonylamino-4-[(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]benzene in THF at -78° was treated with BuLi and then with (R)-glycidyl butyrate followed by stirring for 2 h gave 5(R)-3-[4-[(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]-5-hydroxymethyloxazolidin-2-one. The latter was stirred 15 min. with Et₃N and MeSO₂Cl in CH₂Cl₂ at 0° to give a residue which was stirred at 70° with NaN₃ in DMF to give 5(R)-azidomethyl-3-[4-[(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]oxazolidin-2-one. The latter was hydrogenated in THF/MeOH over Lindlar catalyst to give 5(R)-aminomethyl-3-[4-[(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]oxazolidin-2-one. This was stirred with Et₃N and Ac₂O in THF at 0°-room temperature to give N-[5(S)-3-[4-[(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]oxazolidin-5-ylmethyl]acetamide. The latter showed a min. inhibitory concentration of 0.25 µg/mL against Staphylococcus Aureus Smith.

IT 827014-75-5P 827014-76-6P 827015-45-2P

10536687


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of oxazolidinone antibacterials)

RN 827014-75-5 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 827014-76-6 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 827015-45-2 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:872795 HCAPLUS
 DOCUMENT NUMBER: 141:366217
 TITLE: Preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivatives as antimicrobials
 INVENTOR(S): Renslo, Adam Robert; Gordeev, Mikhail Fedor; Patel, Dinesh Vinoobhai; Gao, Hongwu; Josyula, Vara Prassad Venkata Nagendra
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company. LLC, USA
 SOURCE: PCT Int. Appl., 187 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089943	A1	20041021	WO 2004-IB1135	20040330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2521685	A1	20041021	CA 2004-2521685	20040330
EP 1615916	A1	20060118	EP 2004-724333	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 200409217	A	20060328	BR 2004-9217	20040330
JP 2006522791	T	20061005	JP 2006-506470	20040330

US 20050192325	A1	20050901	US 2004-815589	20040401
US 7279494	B2	20071009		
US 20080090884	A1	20080417	US 2007-868332	20071005
PRIORITY APPLN. INFO.:			US 2003-461134P	P 20030409
			EP 2004-724333	A 20040330
			WO 2004-IB1135	W 20040330
			US 2004-815589	A1 20040401

OTHER SOURCE(S): MARPAT 141:366217
GI



AB Title compds. I [A = oxazolyl, isoxazolyl, etc.; n = 0-1; Y = SOO-2, O, amino; Z = formyl, thioformyl, acyl, etc.; W = CH₂, CO, oximino, etc.; R₁ = H, OH, amino, etc.; R₂₋₃ = H, F; R₄₋₅ = H, Cl, F, Me, NH₂, OH; R₆₋₇ = H, alkyl] are prepared. For example, II is prepared in 9 steps from 2-fluoro-4-nitrobenzaldehyde. II has MIC = 4 µg/mL for *S. aureus* (UC9213). I are antibacterial agents.

IT 777088-83-2P 777089-15-3P 777089-16-4P
777089-23-3P 777089-24-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)

RN 777088-83-2 HCAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 777089-15-3 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-(3-(2-hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-16-4 HCPLUS

CN 2-Oxazolidinone, 3-[3,5-difluoro-4-(3-(2-hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-23-3 HCPLUS

CN 3-Azabicyclo[3.1.0]hexan-2-one, 6-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1S,5R,6R)- (CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 777089-24-4 HCPLUS

CN 3-Azabicyclo[3.1.0]hexan-2-one, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1S,5R,6R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 777090-03-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)

RN 777090-03-6 HCPLUS


CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 24 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:727763 HCPLUS
 DOCUMENT NUMBER: 143:59934
 TITLE: Synthesis and in vitro antibacterial activities of new 3,5-disubstituted oxazolidinone compounds
 Meng, Qingguo; Wang, Qi; Liu, Jun
 AUTHOR(S): Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
 CORPORATE SOURCE: Yaoxue Xuebao (2003), 38(10), 754-759
 SOURCE: CODEN: YHHPAL; ISSN: 0513-4870
 PUBLISHER: Yaoxue Xuebao Bianjibu
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 OTHER SOURCE(S): CASREACT 143:59934
 GI



AB The new oxazolidinone antibacterial agents were designed and synthesized. Oxazolidinones I ($R = 4$ -morpholinyl, 4-phenyl-1-piperazinyl, 4-(4-methoxyphenyl)-1-piperazinyl, 4-benzyl-1-piperidinyl, 1-piperidinyl; $R1 =$ acetamido, 1,2,4-triazol-4-yl, camphorimido, succinimido) were synthesized based on the SAR reported in the literature and their antibacterial activities in vitro were determined. 18 New objective compds. were synthesized, and their structures were determined by IR, 1 H NMR, and FAB-MS. Among the 18 new objective compds., 16 compds. showed antibacterial activity in vitro and I ($R = 4$ -phenyl-1-piperazinyl, $R1 =$ acetamido), I ($R = 4$ -(4-methoxyphenyl)-1-piperazinyl, $R1 =$ acetamido), and I ($R = 4$ -(4-methoxyphenyl)-1-piperazinyl, $R1 =$ camphorimido) showed better antibacterial activities in vitro than ciprofloxacin, sulfamicillin, and vancomycin. Compds. I ($R = 4$ -phenyl-1-piperazinyl, $R1 =$

10536687

1,2,4-triazol-4-yl) and I (R = 4-benzyl-1-piperidinyl, R1 = succinimido) had no antibacterial activity in vitro at all.


IT 556801-57-1P 556801-58-2P 556801-59-3P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and in vitro antibacterial activities of new
3,5-disubstituted oxazolidinone compds.)

RN 556801-57-1 HCPLUS

CN 2-Oxazolidinone, 3-[3-fluoro-4-[(4-phenylmethyl)-1-piperidinyl]phenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 556801-58-2 HCPLUS

CN 3-Azabicyclo[3.2.1]octane-2,4-dione, 3-[(5S)-3-[3-fluoro-4-[(4-phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1,8,8-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 556801-59-3 HCPLUS

Updated Search

CN 2,5-Pyrrolidinedione, 1-[{(5S)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl}methyl] (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 25 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:333714 HCAPLUS
 DOCUMENT NUMBER: 140:357327
 TITLE: Preparation of bicyclic[3.1.0]oxazolidinones and related compounds as antibacterial agents
 INVENTOR(S): Gordeev, Mikhail Fedor; Renslo, Adam; Patel, Dinesh Vinoobhai
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 156 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033451	A1	20040422	WO 2003-US28560	20031003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040127530	A1	20040701	US 2003-677451	20031002
US 6875784	B2	20050405		
CA 2501352	A1	20040422	CA 2003-2501352	20031003
AU 2003278791	A1	20040504	AU 2003-278791	20031003
EP 1549641	A1	20050706	EP 2003-770310	20031003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015106	A	20050809	BR 2003-15106	20031003
JP 2006508934	T	20060316	JP 2004-543288	20031003
MX 2005PA03780	A	20050608	MX 2005-PA3780	20050408
PRIORITY APPLN. INFO.:			US 2002-417735P	P 20021009
			WO 2003-US28560	W 20031003

OTHER SOURCE(S): MARPAT 140:357327
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R₂, R₃ = H, F; R₄, R₅ = H, Cl, F, etc.; R₆, R₇ = H, F, OH, etc.; R₈ = H, F, OH, etc.; A = 5-methyl-2-oxazolidinonyl, 4,5-dihydro-5-Me-oxazoly, dihydro-5-Me-2(3H)-furanyl, etc.; B = (CH₂)_n; n = 0-1; X = N, CH; Y = N, O, S; Z = NHCOR₁, NHCSR₁, CONHR₁, etc.; R₁ = H, NH₂, NH-alkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, condensation of CBZ-protected benzenamine II, e.g., prepared from benzyl 3-pyrroline-1-carboxylate in 5-steps, and (S)-acetic acid 2-acetylaminio-1-chloromethylethyl ester afforded oxazolidinone III in 62% yield. In *S. aureus* Min. Inhibitory Concentration (MIC) growth studies, 6-examples of compds. I exhibited MIC values

ranging from 1-8 µg/mL, i.e., the MIC value of oxazolidinone III was 1 µg/mL. Compds. I are claimed useful for the treatment of skin and eye infections.

IT 681424-73-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681424-73-7 HCPLUS


CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 681424-72-6

CMF C18 H17 F2 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2


IT 681425-60-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of bicyclic[3.1.0]oxazolidinones and related compds. as antibacterial agents)

RN 681425-60-5 HCPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-carboxylic acid, 3-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:



9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 26 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:143139 HCAPLUS
 DOCUMENT NUMBER: 140:181437
 TITLE: Preparation of N-aryl-2-oxazolidinones and their derivatives as antibacterial agents
 INVENTOR(S): Gadwood, Robert C.; Ochoada, Jason M.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014897	A1	20040219	WO 2003-US22486	20030801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2491287	A1	20040219	CA 2003-2491287	20030801
AU 2003259159	A1	20040225	AU 2003-259159	20030801
US 20040072873	A1	20040415	US 2003-632742	20030801
US 7094900	B2	20060822		
EP 1539745	A1	20050615	EP 2003-784775	20030801
EP 1539745	B1	20060329		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013400	A	20050712	BR 2003-13400	20030801
JP 2005537301	T	20051208	JP 2004-527615	20030801
AT 321760	T	20060415	AT 2003-784775	20030801
ES 2258234	T3	20060816	ES 2003-784775	20030801
MX 2005PA01558	A	20050908	MX 2005-PA1558	20050208
PRIORITY APPLN. INFO.:			US 2002-402783P	P 20020812
			WO 2003-US22486	W 20030801

OTHER SOURCE(S): MARPAT 140:181437
 GI



AB Antibacterial agents of formula I [A = 2-oxazolidinone, isoxazoline, furanone, etc.; X, Y = CO, (substituted) NH; R = acylamino, heterocyclo, etc.; R1-R3 = H, halo, Me; R4 = H, alkyl, alkoxy, alkylthio, alkylamino] are prepared. Thus, II was prepared and had MIC of 1 μ g/mL.

IT 658073-58-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryloxazolidinones as antibacterial agents)

RN 658073-58-6 HCPLUS

CN 2-Piperidinone, 5-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:60503 HCPLUS

DOCUMENT NUMBER: 140:128407

TITLE: Preparation of (piperidinophenyl)oxazolidinones



targeting multiple ribonucleoprotein sites as
antibacterial agents
INVENTOR(S):
 Patel, Mahesh V.; Deshpande, Prasad K.; Sindkhedkar,
 Milind D.; Gupte, Shrikant V.; Chugh, Yati; Shetty,
 Nitin; Shukla, Milind C.; Yeole, Ravindra D.; De
 Souza, Noel J.

PATENT ASSIGNEE(S):
SOURCE: PCT Int. Appl., 156 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007489	A2	20040122	WO 2003-IN238	20030710
WO 2004007489	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492194	A1	20040122	CA 2003-2492194	20030710
AU 2003272071	A1	20040202	AU 2003-272071	20030710
EP 1565461	A2	20050824	EP 2003-753912	20030710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
IN 2005MN0003	A	20070504	IN 2005-MN3	20050104
PRIORITY APPLN. INFO.:			US 2002-395164P	P 20020711
			WO 2003-IN238	W 20030710
OTHER SOURCE(S):	CASREACT 140:128407; MARPAT 140:128407			
GI				



AB Title compds. I [wherein R1 = H, (un)substituted (cyclo)alkyl, (un)substituted alkanoyl, arylmercapto, heterocyclithiocarbonyl, etc.; R2, R3 = H, halogen; R4 = alkylsulfonyloxy, (un)substituted alkylthiocarbonylamino, (un)substituted ureido, carbamato, etc.; A, B = independently selected from H, alkyl, CO₂Et, halogen; and salts or solvates thereof] were prepared as antibacterial agents. For example, reaction of (S)-N-[3-[4-(4-cyanomethylideneperidin-1-yl)-3-fluorophenyl]-2-oxooxazolidin-5-ylmethyl]amine with carbon disulfide (69%), followed by addition of sodium methoxide, gave II in 77% yield. II showed 1.56-6.25 µg/mL (MIC) against linezolid resistant strains, such as S. aureus MRSA-32, S. pneumoniae SPN744 and E. faecium 367, 0.2 µg/mL (MIC) against linezolid sensitive strains, such as S. aureus MRSA-32 and S. pneumoniae 49619, 1.56 (MPC) for the treatment of E. faecalis 416 infection, and etc. 3D quant. structure activity relationship (3D-QSAR) showed that the steric contributions of I are over one and half times more than the electrostatic contributions, compared to literature compds. Thus, I and their pharmaceutical compds. targeting multiple ribonucleoprotein sites are useful as antimicrobial agents for treating bacterial infections.

IT 648920-06-3P 648920-10-9P 648920-11-0P
648920-33-6P 648920-34-7P 648920-35-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyanomethylenepiperidinophenyl oxazolidinones targeting multiple RNA sites as antibacterial agents)

RN 648920-06-3 HCPLUS

CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5R)-3-[4-[4-(cyanomethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 648920-10-9 HCPLUS

10536687

CN 1H-1,2,3-Triazole-4-carboxamide, 1-[{[(5R)-3-[4-[4-(cyanomethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl}- (CA INDEX NAME)


Absolute stereochemistry.



RN 648920-11-0 HCAPLUS

CN 4-Piperidineacetonitrile, 1-[4-[(5R)-5-[(4-cyano-1H-1,2,3-triazol-1-yl)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



10536687


RN 648920-33-6 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 648920-34-7 HCAPLUS
CN 1H-1,2,3-Triazole-4-carboxylic acid, 1-[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




10536687


RN 648920-35-8 HCPLUS
CN 1H-1,2,3-Triazole-5-carboxylic acid, 1-[(5R)-3-[4-[4-(1-cyano-2-hydroxyethyl)-1-piperidinyl]-3-fluorophenyl]2-oxo-5-oxazolidinyl]methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



L7 ANSWER 28 OF 31 HCPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:576097 HCPLUS
DOCUMENT NUMBER: 139:85332
TITLE: Preparation of oxazolidone derivatives as antibacterial agents
INVENTOR(S): Liu, Jun; Meng, Qingguo; Jin, Jie; Wu, Yanbin
PATENT ASSIGNEE(S): Institute of Medical and Biological Technology, Chinese Academy of Medical Sciences, Peop. Rep. China
SOURCE: Faming Zhanli Shengqing Gongkai Shuomingshu, 50 pp.
DOCUMENT TYPE: Patent
CODEN: CNXXEV

LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1355165	A	20020626	CN 2001-144613 CN 2001-144613	20011219 20011219
PRORITY APPLN. INFO.:			CASREACT 139:85332; MARPAT 139:85332	
OTHER SOURCE(S): GI				




AB Title compds. I (R1 = H, halo, alkyl, or haloalkyl; R2 = morpholinyl, piperidinyl or its derivative, or 4-substituted piperazinyl; R3 = OH, SH, acyloxy, sulfonyloxy, acylamino, diacylimino, pentabasic heterocyclic group or its derivs.; and when R1 = F, R2 or R3 = morpholinyl or acetamido), useful as antibacterial agents against Gram-pos. bacteria, are prepared. For example, (R)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-5-(hydroxymethyl)-2-oxazolidinone was converted to mesylate, condensed with potassium phthalimide, and treated with aqueous MeNH₂ to give the bactericide linezolid.

IT 556801-55-9P 556801-57-1P 556801-58-2P
556801-59-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolidone derivs. as antibacterial agents)

RN 556801-55-9 HCPLUS
CN 1H-Isocindole-1,3(2H)-dione, 2-[(5S)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]— (CA INDEX NAME)


Absolute stereochemistry.



10536687


RN 556801-57-1 HCAPLUS
CN 2-Oxazolidinone, 3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 556801-58-2 HCAPLUS
CN 3-Azabicyclo[3.2.1]octane-2,4-dione, 3-[(5S)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-1,8,8-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 556801-59-3 HCAPLUS
CN 2,5-Pyrrolidinedione, 1-[(5S)-3-[3-fluoro-4-[4-(phenylmethyl)-1-piperidinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 29 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:736895 HCAPLUS
 DOCUMENT NUMBER: 137:247686
 TITLE: Preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections
 INVENTOR(S): Hester, Jackson B.
 PATENT ASSIGNEE(S): Pharmacia and Upjohn Co., USA
 SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 778,603, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020137754	A1	20020926	US 2002-42916	20020109
US 6642238	B2	20031104		
US 20010047004	A1	20011129	US 2001-778603	20010207
PRIORITY APPLN. INFO.:			US 2000-181640P	P 20000210
			US 2001-778603	B2 20010207

OTHER SOURCE(S): MARPAT 137:247686
 GI



AB Oxazolidinone thioamides, such as I [R1 = H, NH₂, alkylamino, alkenyl, alkyloxy, alkylthio, cycloalkyl, alkyl; R2, R3 = H, F, Cl, alkyl; R4 = CN, acyl, thioacyl, alkyloxyacyl, sulfonylmethylacyl, etc.] which have potent activities against gram-pos. and gram-neg. bacteria, were prepared for therapeutic use in the treatment of bacterial infections particularly of the skin and eye. Thus, PNU 255889 (II) was prepared via a multistep synthetic sequence which included N-acylation of III with MeCH₂CO₂H, S-oxidation with sodium periodate, conversion of the phthalimido group to NH₂ and N-thioacetylation with MeCH₂CS₂Me. The prepared oxazolidinone thioamides were evaluated for min. inhibitory concns. of antibacterial activity against bacterial strains such as *Staphylococcus aureus*, *S. epidermidis*, *Streptococcus pneumoniae*, *Enterococcus faecalis* *Moraxella catarrhalis* and *H. influenzae*. Pharmaceutical formulations for oral, topical, transdermal, and parenteral delivery were discussed.

IT 354578-46-4P 354578-47-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections)

RN 354578-46-4 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[(5S)-3-[3-fluoro-4-[(2-(methylthio)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.


10536687



RN 354578-47-5 HCPLUS

CN 1H-Isindole-1,3(2H)-dione, 2-[(5S)-3-[3-fluoro-4-[4-[2-(methylsulfinyl)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 174649-05-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of oxazolidinone thioamides with piperazine amide substituents
for pharmaceutical use in the treatment of microbial infections)

RN 174649-05-9 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-|(5S)-5-[(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 30 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:597972 HCAPLUS
 DOCUMENT NUMBER: 135:180754
 TITLE: Preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections
 INVENTOR(S): Hester, Jackson B., Jr.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Co., USA
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058885	A1	20010816	WO 2001-US682	20010207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, NE, SN, TD, TG				
CA 2395648	A1	20010816	CA 2001-2395648	20010207
AU 2001034428	A	20010820	AU 2001-34428	20010207
BR 2001007645	A	20021008	BR 2001-7645	20010207
EP 1263742	A1	20021211	EP 2001-906529	20010207
EP 1263742	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003522763	T	20030729	JP 2001-558436	20010207
NZ 520696	A	20040326	NZ 2001-520696	20010207
AT 302762	T	20050915	AT 2001-906529	20010207
ES 2248284	T3	20060316	ES 2001-906529	20010207
IN 2002MN00938	A	20050304	IN 2002-MN938	20020711
MX 2002PA07719	A	20021011	MX 2002-PA7719	20020809

PRIORITY APPLN. INFO.:

US 2000-181640P

P 20000210


OTHER SOURCE(S):

MARPAT 135:180754

WO 2001-US682

W 20010207

GI



AB Oxazolidinone thioamides, such as I [R1 = H, NH2, alkylamino, alkenyl, alkylxyloxy, alkylthio, cycloalkyl, alkyl; R2, R3 = H, F, Cl, alkyl; R4 = CN, acyl, thioacyl, alkylxyacetyl, sulfonylmethylacetyl, etc.] which have potent activities against gram-pos. and gram-neg. bacteria, were prepared for therapeutic use in the treatment of bacterial infections particularly of the skin and eye. Thus, PNU 255889 (II) was prepared via a multistep synthetic sequence which included N-acylation of III with MeSCH2CO2H, S-oxidation with sodium periodate, conversion of the phthalimido group to NH2 and N-thioacetylation with MeCH2CS2Me. The prepared oxazolidinone thioamides were evaluated for min. inhibitory concns. of antibacterial activity against bacterial strains such as *Staphylococcus aureus*, *S. epidermidis*, *Streptococcus pneumoniae*, *Enterococcus faecalis* *Moraxella catarrhalis* and *H. influenzae*. Pharmaceutical formulations for oral, topical, transdermal, and parenteral delivery were discussed.

IT 354578-46-4P 354578-47-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of oxazolidinone thioamides with piperazine amide substituents for pharmaceutical use in the treatment of microbial infections)

RN 354578-46-4 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[(5S)-3-[3-fluoro-4-[4-[2-(methylthio)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-(CA INDEX NAME)

10536687


Absolute stereochemistry.



RN 354578-47-5 HCPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[(5S)-3-[3-fluoro-4-[4-[2-(methylsulfinyl)acetyl]-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl-
(CA INDEX NAME)

Absolute stereochemistry.




IT 174649-05-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolidinone thioamides with piperazine amide substituents
for pharmaceutical use in the treatment of microbial infections)

RN 174649-05-9 HCPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl
ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 31 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:58412 HCAPLUS

DOCUMENT NUMBER: 124:232297

ORIGINAL REFERENCE NO.: 124:43034h,43035a

TITLE: Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections

AUTHOR(S): Brickner, Steven J.; Hutchinson, Douglas K.; Barbachyn, Michael R.; Manninen, Peter R.; Ulanowicz, Debra A.; Garmon, Stuart A.; Grega, Kevin C.; Hendges, Susan K.; Toops, Dana S.; et al.

CORPORATE SOURCE: Upjohn Laboratories, Upjohn Company, Kalamazoo, MI, 49001, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(3), 673-9

PUBLISHER: CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: American Chemical Society


LANGUAGE: Journal English

AB Bacterial resistance development has become a very serious clin. problem for many classes of antibiotics. The 3-aryl-2-oxazolidinones are a relatively new class of synthetic antibacterial agents, having a new mechanism of action which involves very early inhibition of bacterial protein synthesis. Two potent, synthetic oxazolidinones, U-100592 [i.e., (S)-N-[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methylacetamide] and U-100766 [i.e., (S)-N-[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methylacetamide] were prepared, which are currently in clin. development for the treatment of serious multidrug-resistant Gram-pos. bacterial infections caused by strains of staphylococci, streptococci, and enterococci. The in vitro and in vivo (po and i.v.) activities of U-100592 and U-100766 against representative strains are similar to those of vancomycin. U-100592 and U-100766 demonstrate potent in vitro activity against *Mycobacterium tuberculosis*. A novel and practical asym. synthesis of (5S)-(acetamidomethyl)-2-oxazolidinones was developed and was employed for the synthesis of U-100592 and U-100766. This involved the reaction of N-lithioarylcarambates with (R)-glycidyl butyrate, resulting in excellent yields and high enantiomeric purity of the intermediate

10536687

(R)-5-(hydroxymethyl)-2-oxazolidinones.
IT 174649-05-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and bactericidal activity of U-100592 and U-100766)
RN 174649-05-9 HCPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[(5S)-5-[(1,3-dihydro-1,3-dioxo-2H-isindol-2-yl)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



=> file caold		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	212.41	399.35
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-29.60	-29.60

FILE 'CAOLD' ENTERED AT 16:49:21 ON 03 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of

10536687

all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAOLD will be discontinued and removed from associated database clusters.

- . November 22, 2008 - removed from database clusters
- . December 31, 2008 - removed from STN

Content previously available only in CAOLD is now available in CA/CAplus. To learn more about the options available for transferring saved search queries and answer sets to CA/CAplus, contact your STN Service Center.

=> d his

(FILE 'HOME' ENTERED AT 16:42:15 ON 03 OCT 2008)

FILE 'REGISTRY' ENTERED AT 16:42:27 ON 03 OCT 2008

L1	STRUCTURE UPLOADED
L2	30 S LK1
L3	21 S L1
L4	367 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 16:47:13 ON 03 OCT 2008

L5	37 S L4
L6	6 S L5 AND GRAVESTOCK, M?/AU
L7	31 S L5 NOT L6
L8	0 S L7 AND HALES, N?/AU
L9	0 S L7 AND RECK, F?/AU
L10	0 S L7 AND ZHOU, F?/AU

FILE 'CAOLD' ENTERED AT 16:49:21 ON 03 OCT 2008

=> s 14
L11 0 L4

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	399.81
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-29.60

FILE 'REGISTRY' ENTERED AT 16:49:30 ON 03 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 OCT 2008 HIGHEST RN 1056546-78-1
DICTIONARY FILE UPDATES: 2 OCT 2008 HIGHEST RN 1056546-78-1

Updated Search

10536687

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\e-Red
Folder\10524345\dsfaet.str

L12 STRUCTURE UPLOADED

=> s 112
SAMPLE SEARCH INITIATED 16:50:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1509 TO ITERATE

100.0% PROCESSED 1509 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 27850 TO 32510
PROJECTED ANSWERS: 0 TO 0

L13 0 SEA SSS SAM L12

=> s 112 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:50:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 30821 TO ITERATE

100.0% PROCESSED 30821 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L14 0 SEA SSS FUL L12

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\e-Red
Folder\10524345\aerat.str

L15 STRUCTURE UPLOADED

=> s 115
SAMPLE SEARCH INITIATED 16:52:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1509 TO ITERATE

Updated Search

10536687

100.0% PROCESSED 1509 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 27850 TO 32510
PROJECTED ANSWERS: 0 TO 0

L16 0 SEA SSS SAM L15

=> s l16 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:52:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 30821 TO ITERATE

100.0% PROCESSED 30821 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L17 0 SEA SSS FUL L15

=>
Uploading C:\Documents and Settings\brobins0n1\My Documents\e-Red
Folder\10524345\kljl1.str

L18 STRUCTURE UPLOADED

=> s l18
SAMPLE SEARCH INITIATED 16:56:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 147 TO ITERATE

100.0% PROCESSED 147 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2213 TO 3667
PROJECTED ANSWERS: 0 TO 0

L19 0 SEA SSS SAM L18

=> s l18 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 16:56:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2832 TO ITERATE

100.0% PROCESSED 2832 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L20 0 SEA SSS FUL L18